

## PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION  
(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
US Department of Commerce  
United States Patent and Trademark  
Office, PCT  
2011 South Clark Place Room  
CP2/5C24  
Arlington, VA 22202  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 20 June 2001 (20.06.01)	To: Commissioner US Department of Commerce United States Patent and Trademark Office, PCT 2011 South Clark Place Room CP2/5C24 Arlington, VA 22202 ETATS-UNIS D'AMERIQUE in its capacity as elected Office
International application No. PCT/EP00/09584	Applicant's or agent's file reference SPW99.06
International filing date (day/month/year) 25 September 2000 (25.09.00)	Priority date (day/month/year) 24 September 1999 (24.09.99)
<b>Applicant</b> DELEERSNIJDER, Willy et al	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

19 March 2001 (19.03.01)

in a notice effecting later election filed with the International Bureau on:

\_\_\_\_\_

2. The election  was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer  Juan Cruz
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38



REC'D 14 JAN 2002

WIPO

PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference SPW99.06	<b>FOR FURTHER ACTION</b>		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/EP00/09584	International filing date (day/month/year) 25/09/2000	Priority date (day/month/year) 24/09/1999	
International Patent Classification (IPC) or national classification and IPC C07K14/00			
Applicant SOLVAY PHARMACEUTICALS B.V. et al.			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 7 sheets, including this cover sheet.

This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).


These annexes consist of a total of 9 sheets.

3. This report contains indications relating to the following items:

- I    Basis of the report
- II    Priority
- III    Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV    Lack of unity of invention
- V    Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI    Certain documents cited
- VII    Certain defects in the international application
- VIII    Certain observations on the international application

Date of submission of the demand 19/03/2001	Date of completion of this report 09.01.2002
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  SCHEFFZYK, I Telephone No. +49 89 2399 8602





**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP00/09584

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):  
**Description, pages:**

1-56 as originally filed

**Claims, No.:**

1-40 as received on 01/10/2001 with letter of 14/09/2001

**Drawings, sheets:**

1/9-9/9 as originally filed

**Sequence listing part of the description, pages:**

1-28, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.


These elements were available or furnished to this Authority in the following language: , which is:

- the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- the language of publication of the international application (under Rule 48.3(b)).
- the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- contained in the international application in written form.
- filed together with the international application in computer readable form.
- furnished subsequently to this Authority in written form.
- furnished subsequently to this Authority in computer readable form.
- The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP00/09584

- the description, pages:
- the claims, Nos.:
- the drawings, sheets:
5.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)): *(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*
6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:
- the entire international application.
- claims Nos. 27,30,32.
- because:
- the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):
- the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):  
**see separate sheet**
- the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- no international search report has been established for the said claims Nos. 27,30,32.
2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:
- the written form has not been furnished or does not comply with the standard.
- the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**



1

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP00/09584

**1. Statement**

Novelty (N)	Yes:	Claims 6-26,28,29,31,33,34,36,37-40
	No:	Claims 1-5,35
Inventive step (IS)	Yes:	Claims 6-26,28,29,31,33,34,36,37-40
	No:	Claims 1-5,35
Industrial applicability (IA)	Yes:	Claims 1-26,28,29,31,33-36, 38-40
	No:	Claims 37

**2. Citations and explanations**

**see separate sheet**

**VI. Certain documents cited**

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

**see separate sheet**

**VII. Certain defects in the international application**

The following defects in the form or contents of the international application have been noted:  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP00/09584

**SECTION V-----**

The sequences claimed in claims 1-5 are not delimitated from the sequences described in the Database EMBL Nucleotide and Protein Sequences cited in the ISR as "X" documents. Relating to this it is noted that these sequences are publicly available due to their accession numbers (please see also page 43 of present application, last paragraph).

In addition, novelty of claim 35 cannot be acknowledged since any readily available compound may be covered by the scope of said claim.

To sum up: claims 1-5 and 35 do not meet the requirements of Art. 33(2)(3) PCT.

The subject-matter of the remaining claims seems to be novel and inventive since the existence of the claimed receptor was neither taught nor derivable from the documents cited in the ISR.

**SECTION VI-----**

WO 99/55732

WO 00/22131

Howard A. et al., Nature, vol. 406, no. 67991, 2000, pp. 70-74


Hosoya Masaki et al., Journal of Biological Chemistry, vol. 275, no. 38, 22.09.00

Szekeres P. et al., Journal of Biological Chemistry, vol. 275, no. 27, 07.07.00

Fujii R. et al., Journal of Biological Chemistry, vol. 275, no. 28, 14.07.00

**SECTION VII-----**

- 1). Claims 9 and 10 should be checked: it seems to be more appropriate that these claims are directed to an expression vector containing a nucleic acid .....(see also SECTION VIII/1.).)
  
- 2). With respect to the term "incorporated by reference" Applicant's attention is drawn to Guidelines C-II 4.4 and 4.17 PCT.



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP00/09584

- 3). The sequence of the claims should be checked (see e.g. claims 36, 39 and 40).
- 4). Some of present claims appear to be redundant (see e.g. claims 7 and 8 in view of claim 6).
- 5). The replacement of the term "corresponding to" by "comprising" in newly-filed claims violates Art. 34(2)(b) PCT since the IPEA is of the opinion that said term is to be read in the sense of "consisting of".

**SECTION VIII-----**

- 1). For the sake of clarity and in order to render the claimed expression vector clearly and unambiguously novel over readily available expression vectors the term "capable of" used in claims 9 and 10 should be replaced by "comprising" to make clear that the vector contains a sequence encoding IGS4.
- 2). Concerning claim 14 it is noted that the term "IGS4" has no well-recognized technical meaning to a person skilled in the art but is only an internal designation. Thus, with respect to claim 14 a novelty problem may arise since said claim may encompass a readily available membrane preparation which, in addition to IGS4 preparations also may be prepared from the host cells as defined in claim 11-13. For the same reasons an objection under Art. 33(2) might arise also with respect to claims 14, 15 and 36..
- 3). Claims 23 and 24 are unclear (Art. 6 PCT) because they do not **specify** the disorder to be treated.
- 4). Claims 31 and 33 lack technical support by present specification since present application fails to teach an agonist which would be suitable in the method defined in the said claims. The same applies to claims relating to the medical use of presently claimed receptor protein.
- 5). In the broadest sense claim 37 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-




**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP00/09584

matter of these claims (Article 34(4)(a)(i) PCT).



(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number  
**WO 01/25269 A3**(51) International Patent Classification: **C07K 14/705.**  
C12N 15/12, C07K 16/28, C12Q 1/68, A61K 38/17,  
A01K 67/027[NL/NL]: C.J. Van Houtenlaan 36, NL-1381 CP Weesp  
(NL).

(21) International Application Number: PCT/EP00/09584

(74) Agents: **VERHAGE, Marinus**; Octrooibureau Zaan B.V.,  
C.J. Van Houtenlaan 36, NL-1381 CP Weesp et al. (NL).(22) International Filing Date:  
25 September 2000 (25.09.2000)(81) Designated States (national): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,  
UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

**Published:**

– with international search report

(71) Applicant (for all designated States except US): **SOLVAY  
PHARMACEUTICALS B.V.** [NL/NL]; C.J. Van Houtenlaan 36, NL-1381 CP Weesp (NL).(88) Date of publication of the international search report:  
11 October 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.




A3

(54) Title: HUMAN G-PROTEIN COUPLED RECEPTOR

WO 01/25269

(57) **Abstract:** The polynucleotides and polypeptides of the present invention relate to the G-protein coupled receptor family, referred to as IGS4-family. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides, to a vector containing said polynucleotides, a host cell containing such vector and transgenic animals where the IGS4-gene is either over-expressed, misexpressed, underexpressed or suppressed (knock-out animals). The invention further relates to a method for screening compounds capable to act as an agonist or an antagonist of IGS4-family and the use of such IGS4 polypeptides, polynucleotides, agonists or antagonists. Preferred uses of the invention relate to disorders of the nervous system, disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system. The invention also relates to the identification of the cognate ligand of the IGS4 polypeptides the neuropeptides known as neuromedin U.



# INTERNATIONAL SEARCH REPORT

Int'l application No  
PCT/EP 00/09584

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 C07K14/705	C12N15/12	C07K16/28	C12Q1/68	A61K38/17
A01K67/027				

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, STRAND, BIOSIS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES,          4 August 1999 (1999-08-04), XP002131651          HINXTON, GB          cited in the application          AC = AC008571. HGT, Homo sapiens          chromosome 5 clone CIT-HSPC_550M4, WORKING DRAFT SEQUENCE, 42 unordered pieces.          From nt 204886-205679.          abstract</p> <p>----</p> <p style="text-align: center;">-/--</p>	1-5, 9, 17, 18

Further documents are listed in the continuation of box C.

Patent family members are listed in annex

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

20 March 2001

09/04/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel: (+31-70) 340-2040, Tx. 31 651 epo nl.  
 Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.



# INTERNATIONAL SEARCH REPORT

In. [REDACTED] Application No  
PCT/EP 00/09584

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No
X	<p>DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES,            17 February 1996 (1996-02-17),            XP002131652            HINXTON, GB            cited in the application            AC = N45474. EST, yy59b04.rl Homo sapiens            cDNA clone 277807 5'.            abstract</p> <p>---</p> <p>DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES,            9 June 1996 (1996-06-09), XP002131653            HINXTON, GB            cited in the application            AC = W61169. EST, zd31a03.rl Soares fetal            heart NbHH19W Homo sapiens cDNA clone            342220 5'.            abstract</p> <p>---</p> <p>DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES,            3 July 1995 (1995-07-03), XP002131654            HINXTON, GB            cited in the application            AC= H11359. EST, ym13d04.rl Homo sapiens            cDNA clone 47842 5' similar to contains L1            repetitive element            abstract</p> <p>---</p> <p>WO 90 01330 A (BENNETT TERENCE ; GARDINER            SHEILA MARGARET (GB))            22 February 1990 (1990-02-22)            cited in the application</p> <p>abstract            page 1, line 1 -page 5, line 3</p> <p>---</p> <p>TAN C.P. ET AL.,: "Cloning and characterization of a human and murine T-cell orphan G-protein-coupled receptor similar to the growth hormone secretagogue and neuropeptide Y receptors"            GENOMICS,            vol. 52(2), 1998, page 223-229 XP000879493            cited in the application            Fig. 1            the whole document</p> <p>---</p> <p>-/-</p>	1-5, 9, 17, 18
A		6-8, 19, 21, 28-30, 33-35, 38-40
Y		1-5, 11-18




# INTERNATIONAL SEARCH REPORT

In. [REDACTED] Application No  
PCT/EP 00/09584

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MCKEE K.K. ET AL.: "Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neuropeptide receptors" GENOMICS, vol. 46(3), 1997, page 426-434 XP000889897 cited in the application Fig 1 the whole document ---	1-5, 11-18
A	VITA N ET AL: "CLONING AND EXPRESSION OF A COMPLEMENTARY DNA ENCODING A HIGH AFFINITY HUMAN NEUROTENSIN RECEPTOR" FEBS LETTERS, NL, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 317, no. 1/02, 1 February 1993 (1993-02-01), page 139-142 XP002048144 ISSN: 0014-5793 cited in the application the whole document ---	1-5, 11-18
A	DATABASE WPI Section Ch, Week 199632 Derwent Publications Ltd., London, GB; Class B04, AN 1996-318958 XP002131656 & JP 08 143597 A (TAKEDA CHEM IND LTD), 4 June 1996 (1996-06-04) abstract ---	1-5, 11-18, 26-32
A	VITA N ET AL.: "Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 360, no. 2/3, 6 November 1998 (1998-11-06), pages 265-272, XP000879367 cited in the application the whole document ---	26-32
A	US 5 482 835 A (KING KLIM ET AL) 9 January 1996 (1996-01-09) cited in the application abstract; examples 3-5 ---	26-32
P, X	WO 99 55732 A (AHMAD SULTAN ;CAO JACK (CA); DONNELL DAJAN O (CA); WALKER PHILIPPE) 4 November 1999 (1999-11-04) abstract page 2, line 1 -page 5, line 17; figure 2 SEQ.ID.N.1 ---	1-5, 9, 11-18, 23-26

-/-




**INTERNATIONAL SEARCH REPORT**

In:	Application No
PCT/EP 00/09584	

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No
P,X	WO 00 22131 A (ARENA PHARMACEUTICALS INC ; GORE MARTIN (US); LIAW CHEN W (US); LIN) 20 April 2000 (2000-04-20) abstract SEQ.ID.N.12 page 3, line 5-14; example 1 ----	1-5, 9, 11-18, 23-26
P,X	HOWARD ANDREW D ET AL: "Identification of receptors for neuromedin U and its role in feeding." NATURE (LONDON), vol. 406, no. 6791, 2000, pages 70-74, XP000926239 ISSN: 0028-0836 the whole document ----	1-40
P,X	HOSOYA MASAKI ET AL: "Identification and functional characterization of a novel subtype of neuromedin U receptor." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 38, 22 September 2000 (2000-09-22), pages 29528-29532, XP002163224 ISSN: 0021-9258 the whole document ----	1-40
P,X	SZEKERES PHILIP G ET AL: "Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 27, 7 July 2000 (2000-07-07), pages 20247-20250, XP002163225 ISSN: 0021-9258 the whole document ----	6-8, 19, 21, 28-30, 33-35, 38-40
P,X	FUJII RYO ET AL: "Identification of neuromedin U as the cognate ligand of the orphan G protein-coupled receptor FM-3." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 28, 14 July 2000 (2000-07-14), pages 21068-21074, XP002163226 ISSN: 0021-9258 the whole document ----	6-8, 19, 21, 28-30, 33-35, 38-40
		-/-




## INTERNATIONAL SEARCH REPORT

In [REDACTED] Application No.  
PCT/EP 00/09584

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
T	RADDATZ RITA ET AL: "Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 42, 20 October 2000 (2000-10-20), pages 32452-32459, XP002163227 ISSN: 0021-9258 the whole document ----	1-40
T	SHAN LIXIN ET AL: "Identification of a novel neuromedin U receptor subtype expressed in the central nervous system." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 50, 15 December 2000 (2000-12-15), pages 39482-39486, XP002163228 ISSN: 0021-9258 the whole document -----	1-40



# INTERNATIONAL SEARCH REPORT

International Application No. PCT/EP 00 09584

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

### Continuation of Box I.1

Although claims 23,24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claim 25 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

### Continuation of Box I.2

Claims Nos.: 27,30,32

Claims 27,30 and 32, refer to an agonist and antagonist of polypeptide of claim 1 without giving a true technical characterization. Moreover, no such compounds are defined in the application and in consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported according to Art. 5 and 6 PCT.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.




# INTERNATIONAL SEARCH REPORT

Information on patent family members


In Application No  
PCT/EP 00/09584

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9001330	A 22-02-1990	NONE			
JP 8143597	A 04-06-1996	NONE			
US 5482835	A 09-01-1996	US	5739029 A	14-04-1998	
		AU	652576 B	01-09-1994	
		AU	8511591 A	15-04-1992	
		CA	2092717 A	14-03-1992	
		EP	1029915 A	23-08-2000	
		EP	0548165 A	30-06-1993	
		IE	913242 A	25-02-1992	
		JP	6500693 T	27-01-1994	
		WO	9205244 A	02-04-1992	
WO 9955732	A 04-11-1999	AU	4298099 A	16-11-1999	
		EP	1071714 A	31-01-2001	
WO 0022131	A 20-04-2000	AU	6299199 A	01-05-2000	
		AU	6430799 A	01-05-2000	
		WO	0021987 A	20-04-2000	
		WO	0022129 A	20-04-2000	
		AU	3790400 A	13-06-2000	
		WO	0031258 A	02-06-2000	



**Claims**

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
  - a) a nucleotide sequence encoding the IGS4 polypeptide according to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8;
  - b) a nucleotide sequence encoding the polypeptide encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands, in particular a nucleotide sequence comprising SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7;
  - c) a nucleotide sequence having at least 80 % (preferably at least 90%) sequence identity over its entire length to the nucleotide sequence of (a) or (b);
  - d) a nucleotide sequence which is complimentary to the nucleotide sequence of (a) or (b) or (c).
2. The polynucleotide of claim 1 wherein said polynucleotide comprises the nucleotide sequence contained in SEQ ID NO: 1 encoding the IGS4 polypeptide of SEQ ID NO: 2 or the nucleotide sequence contained in SEQ ID NO: 3 encoding the IGS4 polypeptide of SEQ ID NO: 4 or the nucleotide sequence contained in SEQ ID NO: 5 encoding the IGS4 polypeptide of SEQ ID NO: 6 or the nucleotide sequence contained in SEQ ID NO: 7 encoding the IGS4 polypeptide of SEQ ID NO: 8.
3. The polynucleotide of claim 1 wherein said polynucleotide comprises a nucleotide sequence that is at least 80% identical to that of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 or to the sequence of the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands over its entire length.
4. The polynucleotide of claim 3 which is the polynucleotide of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 or the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands.
5. The polynucleotide of claim 1-4 which is DNA or RNA.



6. An isolated nucleotide sequence encoding an IGS4 neuromedin receptor protein comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8, preferably a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25.
7. An isolated nucleotide sequence of claim 6 encoding an IGS4 neuromedin receptor protein comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8, said protein exhibiting expression in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea.
8. An isolated nucleotide sequence encoding an IGS4 neuromedin receptor protein comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8, preferably a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, said protein exhibiting expression in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea, and said nucleotide sequence being selected from the group of nucleotide sequences as defined in the claims 1 to 5.
9. A DNA or RNA molecule comprising an expression vector, wherein said expression vector is capable of producing an IGS4 polypeptide comprising an amino acid sequence, which has at least 80% identity with the polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8 or with the polypeptide encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands, when said expression vector is present in a compatible host cell.
10. An isolated DNA or RNA molecule comprising an expression vector, wherein said expression vector is capable of producing an IGS4 neuromedin receptor protein comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ




ID NO:6 or SEQ ID NO:8, preferably a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, and exhibiting expression in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea.

11. A host cell comprising the expression system of claim 9 or 10.
12. A host cell according to claim 11 which is a yeast cell.
13. A host cell according to claim 11 which is an animal cell.
14. IGS4 receptor membrane preparation derived from a cell according to claim 11-13.
15. A process for producing an IGS4 polypeptide comprising culturing a host of claim 11-13 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.
16. A process for producing a cell which produces an IGS4 polypeptide comprising transforming or transfecting a host cell with the expression system of claim 9 or 10 such that the host cell, under appropriate culture conditions, produces an IGS4 polypeptide.
17. An IGS4 polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO: 2, SEQ NO: 4, SEQ NO: 6 or SEQ NO: 8 or to the polypeptide encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands over its entire length.
18. The polypeptide of claim 17 which comprises the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands.



19. An isolated IGS4 neuromedin receptor protein comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8, preferably of a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25.
20. An isolated IGS4 neuromedin receptor protein of claim 19 comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8, said protein exhibiting expression in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea.
21. An isolated IGS4 neuromedin receptor protein comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8, preferably a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, said protein exhibiting expression in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea, and said amino acid sequence being selected from the group of amino acid sequence as defined in the claims 17-18.
22. An antibody immunospecific for the IGS4 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 of claim 17-21.
23. Use of:
  - (a) a therapeutically effective amount of an agonist to the IGS4 neuromedin receptor polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 of claim 17-21; and/or
  - (b) an isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the IGS4 polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the polypeptide encoded by



the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands over its entire length; or a nucleotide sequence complementary to one of said nucleotide sequences in a form so as to effect production of said receptor activity in vivo; and/or

(c) an isolated polynucleotide comprising a nucleotide sequence that encodes an IGS4 neuromedin receptor protein comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8, preferably a mammalian IGS4 neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25,

for the preparation of a medicament for the treatment of a subject suffering from a disease related to expression or activity of the IGS4 neuromedin receptor polypeptide, in need of enhanced activity or expression of IGS4 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 of claim 17-21.

24. Use of:

(a) a therapeutically effective amount of an antagonist to the IGS4 neuromedin receptor polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 of claim 17-21; and/or

(b) a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding the IGS4 neuromedin receptor polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 of claim 17-21; and/or

(c) a therapeutically effective amount of a polypeptide that competes with the IGS4 neuromedin receptor polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 of claim 17-21 for its ligand,

for the preparation of a medicament for the treatment of a subject suffering from a disease related to expression or activity of the IGS4 neuromedin receptor polypeptide, having need to inhibit activity or expression of IGS4 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 of claim 17-21.



25. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of the IGS4 neuromedin receptor polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 of claim 17-21 in a subject, comprising:
  - (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said IGS4 polypeptide in the genome of said subject in a sample derived from said subject; and/or
  - (b) analyzing for the presence or amount of said IGS4 polypeptide expression in a sample derived from said subject.
26. A method for identifying agonists to the IGS4 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 of claim 17-21, comprising:
  - (a) contacting a cell which produces said IGS4 polypeptide with a test compound; and
  - (b) determining whether the test compound effects a signal generated by activation of the IGS4 polypeptide.
27. An agonist identified by the method of claim 26.
28. A method for identifying agonists to the IGS4 neuromedin receptor protein comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8, preferably to the mammalian IGS4 neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, comprising:
  - (a) contacting a cell which produces said IGS4 neuromedin receptor protein with a test compound; and
  - (b) determining whether the test compound effects a signal generated by activation of the IGS4 neuromedin receptor protein.
29. A method for identifying agonists to the IGS4 neuromedin receptor protein comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 according to claim 28, wherein said agonists are effective with regard to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal



muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system.

30. An agonist identified by the method of claim 28 or 29, preferably an agonist being effective with regard to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system.
31. A method for identifying antagonists to the IGS4 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 of claim 17-21 comprising:
  - (a) contacting a cell which produces said IGS4 polypeptide with an agonist; and
  - (b) determining whether the signal generated by said agonist is diminished in the presence of a candidate compound.
32. An antagonist identified by the method of claim 31.
33. A method for identifying antagonists to the IGS4 neuromedin receptor protein comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8, preferably to the mammalian IGS4 neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, comprising:
  - (a) contacting a cell which produces said IGS4 neuromedin receptor protein with an agonist; and
  - (b) determining whether the signal generated by said agonist is diminished in the presence of a candidate compound.
34. A method for identifying antagonists to the IGS4 neuromedin receptor protein comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 according to claim 33, wherein said antagonists are effective with regard to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal



muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system.

35. An antagonist identified by the method of claim 33 or 34, preferably an antagonist being effective with regard to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system.
36. A recombinant host cell produced by a method of claim 16 or a membrane thereof expressing an IGS4 polypeptide.
37. A method of creating a genetically modified non-human animal for IGS4 neuromedin receptor related disorders comprising the steps of:
  - (a) ligating the coding portion of a nucleic acid molecule, consisting essentially of a nucleic acid sequence encoding a protein having the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands, to a regulatory sequence which is capable of driving high level gene expression or expression in a cell type in which the gene is not normally expressed in said animal; or
  - (b) isolation and engineering the coding portion of a nucleic acid molecule, consisting essentially of a nucleic acid sequence encoding a protein having the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands, and reintroducing said sequence in the genome of said animal in such a way that the endogenous gene alleles, encoding a protein having the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands, are fully or partially inactivated.



38. A method of determining whether a substance is a potential ligand of IGS4 receptor comprising the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8, comprising:
  - (a) contacting cells expressing the receptor of one of the claims 17-21 or one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8, or contacting a receptor membrane preparation comprising one of said receptors of one of the claims 17-21 or one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8 with labeled neuromedin U in the presence and in the absence of the substance; and
  - (b) measuring the binding of neuromedin U to said IGS4.
39. A polypeptide according to any of the claims 17-21, further being characterized in that said polypeptide binds neuromedin U, preferably neuromedin U-8, neuromedin U-23 and/or neuromedin U-25, showing at least an affinity of about  $\log EC_{50} = -6$ .
40. A polypeptide according to any of the claims 17-21, further being characterized in that said polypeptide binds neuromedin U, preferably neuromedin U-8, neuromedin U-23 and/or neuromedin U-25, showing at least an affinity of about  $\log EC_{50} = -9$ .



WO 01/25269 A2



**Published:**

*Without international search report and to be republished upon receipt of that report.*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**Description**

5        The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a G-protein coupled receptor (GPCR), hereinafter referred to as IGS4. IGS4 exists in two polymorphic forms, hereinafter referred to as IGS4A and IGS4B. The invention also relates to inhibiting or activating the action of such 10 polynucleotides and polypeptides, to a vector containing said polynucleotides, a host cell containing such vector and transgenic animals where the IGS4-gene is either overexpressed, misexpressed, underexpressed and/or suppressed (knock-out animals). The invention further relates to a method for screening compounds capable to act as an agonist or an antagonist of said G-protein coupled receptor IGS4, and to the cognate ligand of IGS4.

15

**BACKGROUND OF THE INVENTION**

It is well established that many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second messengers; e.g., 20 cAMP (Lefkowitz, *Nature*, 1991, 351:353-354). Herein these proteins are referred to as proteins participating in pathways with G-proteins. Some examples of these proteins include the GPC receptors, such as those for adrenergic agents and dopamine (Kobilka, B.K., et al., *Proc. Natl. Acad. Sci., USA*, 1987, 84:46-50; Kobilka, B.K., et al., *Science*, 1987, 238:650-656; Bunzow, J.R., et al., *Nature*, 1988, 25 336:783-787), G-proteins themselves, effector proteins, e.g., phospholipase C, adenylate cyclase, and phosphodiesterase, and actuator proteins, e.g., protein kinase A and protein kinase C (Simon, M.I., et al., *Science*, 1991, 252:802-8).

For example, in one form of signal transduction, upon hormone binding to a GPCR the receptor 30 interacts with the heterotrimeric G-protein and induces the dissociation of GDP from the guanine nucleotide-binding site. At normal cellular concentrations of guanine nucleotides, GTP fills the site immediately. Binding of GTP to the  $\alpha$  subunit of the G-protein causes the dissociation of the G-protein from the receptor and the dissociation of the G-protein into  $\alpha$  and  $\beta\gamma$  subunits. The GTP-carrying form then binds to activated adenylate cyclase. Hydrolysis of GTP to GDP, catalyzed by the G-protein itself ( $\alpha$  subunit possesses an intrinsic GTPase activity), returns the G-protein to its basal, inactive form. The 35 GTPase activity of the  $\alpha$  subunit is, in essence, an internal clock that controls an on/off switch. The GDP bound form of the  $\alpha$  subunit has high affinity for  $\beta\gamma$  and subsequent reassociation of  $\alpha$ GDP with  $\beta\gamma$  returns the system to the basal state. Thus the G-protein serves a dual role, as an intermediate that relays the signal from receptor to effector (in this example adenylate cyclase), and as a clock that controls the duration of the signal.



5       The membrane bound superfamily of G-protein coupled receptors has been characterized as having seven putative transmembrane domains. The domains are believed to represent transmembrane  $\alpha$ -helices connected by extracellular or cytoplasmic loops. G-protein coupled receptors include a wide range of biologically active receptors, such as hormone, viral, growth factor and neuropeptoids.

10      The G-protein coupled receptor family includes dopamine receptors which bind to neuroleptic drugs used for treating CNS disorders. Other examples of members of this family include, but are not limited to calcitonin, adrenergic, neuropeptideY, somastatin, neuropeptides, neurotensin, neurokinin, capsaicin, VIP, CGRP, CRF, CCK, bradykinin, galanin, motilin, nociceptin, endothelin, cAMP, adenosine, muscarinic, acetylcholine, serotonin, histamine, thrombin, kinin, follicle stimulating hormone, opsin, endothelial differentiation gene-1, rhodopsin, odorant, and cytomegalovirus receptors.

15      Most G-protein coupled receptors have single conserved cysteine residues in each of the first two extracellular loops which form disulfide bonds that are believed to stabilize functional protein structures. The 7 transmembrane regions are designated as TM1, TM2, TM3, TM4, TM5, TM6 and TM7. The cytoplasmic loop which connects TM5 and TM6 may be a major component of the G-protein binding domain.

20      Most G-protein coupled receptors contain potential phosphorylation sites within the third cytoplasmic loop and/or the carboxy terminus. For several G-protein coupled receptors, such as the  $\beta$ -adrenoreceptor, phosphorylation by protein kinase A and/or specific receptor kinases mediates receptor desensitization.

25      Recently, it was discovered that certain GPCRs, like the calcitonin-receptor like receptor, might interact with small single pass membrane proteins called receptor activity modifying proteins (RAMP's). This interaction of the GPCR with a certain RAMP is determining which natural ligands have relevant affinity for the GPCR-RAMP combination and regulate the functional signaling activity of the complex (McLathie, L.M. et al., Nature (1998) 393:333-339).

30      For some receptors, the ligand binding sites of G-protein coupled receptors are believed to comprise hydrophilic sockets formed by several G-protein coupled receptor transmembrane domains, said sockets being surrounded by hydrophobic residues of the G-protein coupled receptors. The hydrophilic side of each G-protein coupled receptor transmembrane helix is postulated to face inward and form a polar ligand-binding site. TM3 has been implicated in several G-protein coupled receptors as having a ligand-binding site, such as the TM3 aspartate residue. TM5 serines, a TM6 asparagine and TM6 or TM7 phenylalanines or tyrosines are also implicated in ligand binding.



G-protein coupled receptors can be intracellularly coupled by heterotrimeric G-proteins to various intracellular enzymes, ion channels and transporters (see, Johnson et al., Endoc. Rev., 1989, 10:317-331). Different G-protein  $\alpha$ -subunits preferentially stimulate particular effectors to modulate various biological functions in a cell. Phosphorylation of cytoplasmic residues of G-protein coupled receptors has been identified as an important mechanism for the regulation of G-protein coupling of some G-protein coupled receptors. G-protein coupled receptors are found in numerous sites within a mammalian host.

Receptors - primarily the GPCR class - have led to more than half of the currently known drugs (Drews, Nature Biotechnology, 1996, 14: 1516). This indicates that these receptors have an established, proven history as therapeutic targets. Clearly there is a need for identification and characterization of further receptors which can play a role in preventing, ameliorating or correcting dysfunctions or diseases, including, but not limited to PNS, psychiatric and CNS disorders, including schizophrenia, episodic paroxysmal anxiety (EPA) disorders such as obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), phobia and panic, major depressive disorder, bipolar disorder, Parkinson's disease, general anxiety disorder, autism, delirium, multiple sclerosis, Alzheimer disease/dementia and other neurodegenerative diseases, severe mental retardation, dyskinesias, Huntington's disease, Tourett's syndrome, tics, tremor, dystonia, spasms, anorexia, bulimia, stroke, addiction/dependency/craving, sleep disorder, epilepsy, migraine; attention deficit/hyperactivity disorder (ADHD); cardiovascular diseases, including heart failure, angina pectoris, arrhythmias, myocardial infarction, cardiac hypertrophy, hypotension, hypertension – e.g. essential hypertension, renal hypertension, or pulmonary hypertension, thrombosis, arteriosclerosis, cerebral vasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral infarction, peripheral vascular disease, Raynaud's disease, kidney disease – e.g. renal failure; dyslipidemias; obesity; emesis; gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), motility disorders and conditions of delayed gastric emptying, such as post operative or diabetic gastroparesis, and diabetes, ulcers – e.g. gastric ulcer; diarrhoea; other diseases including osteoporosis; inflammations; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; chemotherapy induced injury; tumor invasion; immune disorders; urinary retention; asthma; allergies; arthritis; benign prostatic hypertrophy; endotoxin shock; sepsis; complication of diabetes mellitus; and gynaecological disorders.

#### SUMMARY OF THE INVENTION

In one aspect, the invention relates to IGS4 polypeptides (including the IGS4A and IGS4B polypeptide polymorphs), polynucleotides and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such IGS4 polypeptides, polynucleotides and recombinant materials. Such uses include, but are not limited to, use as a therapeutic target and for the treatment of PNS, psychiatric and CNS disorders, including schizophrenia, episodic paroxysmal



anxiety (EPA) disorders such as obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), phobia and panic, major depressive disorder, bipolar disorder, Parkinson's disease, general anxiety disorder, autism, delirium, multiple sclerosis, Alzheimer disease/dementia and other neurodegenerative diseases, severe mental retardation, dyskinesias, Huntington's disease, Tourette's  
5 syndrome, tics, tremor, dystonia, spasms, anorexia, bulimia, stroke, addiction/dependency/craving, sleep disorder, epilepsy, migraine; attention deficit/hyperactivity disorder (ADHD); cardiovascular diseases, including heart failure, angina pectoris, arrhythmias, myocardial infarction, cardiac hypertrophy, hypotension, hypertension – e.g. essential hypertension, renal hypertension, or pulmonary hypertension, thrombosis, arteriosclerosis, cerebral vasospasm, subarachnoid hemorrhage, cerebral  
10 ischemia, cerebral infarction, peripheral vascular disease, Raynaud's disease, kidney disease – e.g. renal failure; dyslipidemias; obesity; emesis; gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), motility disorders and conditions of delayed gastric emptying, such as post operative or diabetic gastroparesis, and diabetes, ulcers – e.g. gastric ulcer; diarrhoea; other diseases including osteoporosis;  
15 inflammations; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; chemotherapy induced injury; tumor invasion; immune disorders; urinary retention; asthma; allergies; arthritis; benign prostatic hypertrophy; endotoxin shock; sepsis; complication of diabetes mellitus; and gynaecological disorders, among others. Preferred uses of the invention relate to disorders of the nervous system, including the central nervous system (CNS)  
20 and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system.

In still another aspect, the invention relates to methods to identify agonists and antagonists using  
25 the materials provided by the invention, and treating conditions associated with IGS4 imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate IGS4 activity or levels. A further aspect of the invention relates to animal-based systems which act as models for disorders arising from aberrant expression or activity of IGS4. Preferred agonists or antagonists identified according to the present invention are those which are  
30 suited for the treatment of disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system.

35 The invention also relates to the identification of the cognate ligand of the IGS4 polypeptides of the invention. High affinity binding to said IGS4 polypeptides is found for the neuropeptides known as neuromedin U.



**Table 1: IGS4A-DNA of SEQ ID NO: 1 and SEQ ID NO: 3**

5' -

5	GGCTCAGCTTGAAACAGAGCCTCGTACCAGGGGAGGCTCAGGCCTTGGATTTAATGTCA GGGATGGAAAAACTTCAGAACATGCTTCCTGGATCTACCAGCAGAAACTAGAACAGATCCATT CAGAAACACCTGAACAGCACCGAGGAGTATCTGGCCTCCTCTGCCGACCTCGGCGCAGC CACTTCTTCCTCCCCGTGTCTGTGGTGTATGTGCCAATTTTGTGGTGGGGTCATTGGC AATGTCCCTGGTGTGCCCTGGTATTCTGCAGCACCCAGGCTATGAAGACGCCAACCAACTAC		
10	TACCTCTTCAGCCTGGCGGTCTCTGACCTCCTGGCCTGCTCCTTGAATGCCCTGGAG GTCTATGAGATGTGGCGCAACTACCCCTTCTGTCGGGCCGTGGCTGCTACTTCAAG ACGGCCCTCTTGAGACCGTGTGCCCTCCATCCTCAGCATTCAACCACCGTCAGCGTG GAGCGCTACGTGGCCATCCTACACCCGTTCCGCGCCAAACTGCAGAGCACCCGGCGCCGG GCCCTCAGGATCCTCGCATCGTCTGGGCTTCTCCGTCTTCTCCCTGCCAACACC		
15	AGCATCCATGGCATCAAGTCCACTACTTCCCCAATGGGTCCCTGGTCCCAGGTTGGCC ACCTGTACGGTCATCAAGCCATGTGGATCTACAATTTCATCATCCAGGTACCTCCTTC CTATTCTACCTCCTCCCCATGACTGTCTCAGTGTCTACTACCTCATGGCACTCAGA CTAAAGAAAGACAAATCTTGTAGGCAGATGAAGGGAATGCAAATATTCAAAGACCCCTGC AGAAAATCAGTCAACAAGATGCTGTTGTCTGGTCTTAGTGTGTTGCTATCTGTTGGCC		
20	CCGTTCCACATTGACCGACTCTTCTTCAGCTTGAGGAGTGGAGTGAATCCCTGGCT GCTGTGTTCAACCTCGTCCATGTGGTGTCAAGGTGTCTTCTTACCTGAGCTCAGCTGTC AACCCCATATTCTATAACCTACTGTCTCGCCGCTTCCAGGCAGCATTCCAGAATGTGATC TCTTCTTCCACAAACAGTGGCACTCCCAGCATGACCCACAGTTGCCACCTGCCAGCGG AACATCTTCCGTACAGAAATGCCACTTGTGGAGCTGACCGAAGATATAGGTCCCCAATT 25	CCATGTCAGTCATCCATGCACAACTCTCACCTCCAACAGCCCTCTCTAGTGAACAGATG TCAAGAACAAACTATCAAAGCTTCCACTTAACAAACCTGAATTCTTCAGAGCTGACT CTCCTCTATGCCCTAAAACCTCAGAGAGGAACATCCCATAATGTATGCCCTCTCATATGA TATTAGAGAGGTAGAATGGCTCTTACAACCTCATGTACCCATTGCTAGTTTTTTTTTA ATAAAACGTGAAAACGTGAGAGTTAGATCTGGTTCAAAACCCAAGACTGCCTGATTTTAG 30	TTATCTTCCACTATCTTAACCTGCCCTCATGCCCTTCACTAGTTCATGCCAAGAACGTGA CTGGAAAGGCATGGCACCTACCTTGATTAATTCCATTAATGGAAATGGTTCGTCTG AGTCATCTACGTTCCGAGTCAGGCTGTCACTCCTACTA - 3'



Table 2: IGS4B-DNA of SEQ ID NO: 5 and SEQ ID NO: 7

5' -


5 GGCTCAGCTTGAACAGAGCCTCGTACCAGGGGAGGCTCAGGCCTTGGATTTAATGTCA  
 GGGATGGAAAAACTTCAGAACATGCTTCCCTGGATCTACCAGCAGAAACTAGAAGATCCATT  
 CAGAAACACCTGAACAGCACCGAGGAGTATCTGGCCTTCCCTGCGGACCTCGGCGCAGC  
 CACTTCTTCCCTCCCCGTGTCTGTGGTGTATGTGCCAATTTGTGGTGGGGTCATTGGC  
 AATGTCCCTGGTGTGCCTGGTATTCTGCAGCACCAAGGCTATGAAGACGCCACCAACTAC  
 TACCTCTTCAGCCTGGCGGTCTTGACCTCCTGGTCTGCTCCTTGAATGCCCTGGAG  
 10 GTCTATGAGATGTGGCGCAACTACCCCTTCTTGTTCGGGCCGTGGCTGCTACTTCAAG  
 ACGGCCCTTTGAGACCCTGTGCTTCGCCTCCATCCTCAGCATCACCAACCGTCAGCGTG  
 GAGCGCTACGTGGCCATCCTACACCCGTTCCCGGCCAACTGCAGAGCACCCGGCGCCGG  
 GCCCTCAGGATCCTCGGCATCGTCTGGGCTTCTCCGTGCTTCTCCCTGCCAACACC  
 AGCATCCATGGCATCAAGTCCACTACTTCCCAATGGGTCCTGGTCCCAGGTTGCC  
 15 ACCTGTACGGTCATCAAGCCATGTGGATCTACAATTCTACATCCAGGTACCTCC  
 CTATTCTACCTCCTCCCCATGACTGTCTCAGTGTCTACTACCTCATGGCACTCAGA  
 CTAAAAGAAAGACAAATCTTGTAGGCAGATGAAGGAAATGCAAATATTCAAAGACCC  
 AGAAAATCAGTCAACAAAGATGCTGTTGTCTGGTCTTAGTGTGCTATCTGTTGGCC  
 CCGTCCACATTGACCGACTCTTCTCAGCTTGTGGAGGAGTGGACTGAATCCCTGGCT  
 20 GCTGTGTTCAACCTCGTCATGTGGTGTCAAGGTGTCTTATTCTACCTGAGCTCAGCTGTC  
 AACCCCAATTCTATAACCTACTGTCTCGCCGCTTCCAGGCAGCATTCCAGAATGTGATC  
 TCTTCTTCCACAAACAGTGGCACTCCAGCATGACCCACAGTTGCCACCTGCCAGCGG  
 AACATCTTCCCTGACAGAATGCCACTTGTGGAGCTGACCGAAGATATAGGTCCCCAATT  
 CTATGTCAGTCATCCGTGCACAACACTCACCCTCCAAACAGCCCTCTAGTGAACAGATG  
 25 TCAAGAACAAACTATCAAAGCTTCACTTTAACAAAACCTGAATTCTTCAGAGCTGACT  
 CTCCCTCTATGCCTCAAAACTTCAGAGAGGAACATCCCATAATGTATGCCTCTCATATGA  
 AATTAGAGAGGTAGAATGGCTCTACAACCTCATGTACCCATTGCTAGTTTTTTTTTA  
 ATAAAACGTGAAACTGAGAGTTAGATCTGGTTCAAAACCCAAGACTGCCTGATTTTAG  
 TTATCTTCCACTATCTTAACCTGCCTCATGCCCTTCACTAGTTCATGCCAAGAACGTGA  
 30 CTGGAAAGGCATGGCACCTATACCTTGATTAATTCCATTAATGGAAATGGTTCGTC  
 AGTCATCTACGTTCCGAGTCAGGCTGTCACTCCTACTA - 3'



Table 3: IGS4A-64-DNA of SEQ ID NO: 9 and SEQ ID NO: 11

5' -

5 GGCTCAGCTTGAACAGAGCCTCGTACCAGGGAGGCTCAGGCCTTGGATTTAATGTCA  
 GGGATGGAAAAACTTCAGAACATGCTCCTGGATCTACCAGCAGAAACTAGAAAGATCCATT  
 CAGAAACACCTGAACAGCACCGAGGAGTATCTGCCCTCTGCGGACCTGGCGCAGC  
 CACTTCTTCCTCCCCGTGTCTGTGGTGTATGTGCCAATTTGTGGTGGGGTCATTGGC  
 AATGTCTCGGTGTGCCTGGTATTCTGCAGCACCGAGCTATGAAGACGCCACCAACTAC  
 10 TACCTCTTCAGCCTGGCGGTCTTGACCTCCTGGCCTGCTCCTTGGAAATGCCCTGGAG  
 GTCTATGAGATGTGGCGCAACTACCCCTTCTTGTTCGGGCCGTGGCTGCTACTTCAAG  
 ACGGCCCTTTGAGACCGTGTGCTCGCCTCATCCTCAGCATCACCACCGTCAGCGTG  
 GAGCGCTACGTGGCCATCCTACACCCGTTCCCGGCCAAACTGCAGAGCACCCGGCGCCGG  
 GCCCTCAGGATCCTCGGCATCGTCTGGGCTTCTCCGTGCTCTCTCCCTGCCAACACC  
 15 AGCATCCATGGCATCAAGTCCACTACTTCCCCAATGGTCCCTGGTCCCAGGTTGGCC  
 ACCTGTACGGTCATCAAGCCATGTGGATCTACAATTCTACATCCAGGTACCTCCTTC  
 CTATTCTACCTCCTCCCCATGACTGTCTACAGTGTCTACTACCTCATGGCACTCAGA  
 CTAAAGAAAGACAAATCTTGTAGGCAGATGAAGGAAATGCAAATATTCAAAGACCCCTGC  
 AGAAAATCAGTCACAAAGATGCTGTCTTGAGGAGTGGAGTGAATCCCTGGCTGCTG  
 20 TGTTCAACCTCGTCCATGTGGTGTCAAGGTGTCTTCTACCTGAGCTCAGCTGTCAACC  
 CCATTATCTATAACCTACTGTCTCGCCGCTTCCAGGCAGCATCCAGAATGTGATCTCTT  
 CTTCCACAAACAGTGGCACTCCCAGCATGACCCACAGTTGCCACCTGCCAGCGGAACA  
 TCTTCCGTACAGAAATGCCACTTTGTGGAGCTGACCGAAGATATAGGTCCCCATTCCAT  
 GTCACTGCACAACTCTCACCTCCAAACAGCCCTCTAGTGAACAGATGTCAA  
 25 GAACAAACTATCAAAGCTTCACTTTAACAAAACCTGAATTCTTCAGAGCTGACTCTCC  
 TCTATGCCTCAAAACTTCAGAGAGGAACATCCCATAATGTATGCCTCTCATATGATATT  
 AGAGAGGTAGAATGGCTTTACAACCTCATGTACCCATTGCTAGTTTTTTTTAATAA  
 ACGTGAAAACGTGAGAGTTAGATCTGGTTCAAAACCAAGACTGCCCTGATTAGTTAT  
 CTTCCACTATCCTAACTGCCTCATGCCCTCACTAGTTCATGCCAAGAACGTGACTGG  
 30 AAAGGCATGGCACCTATACCTTGATTAATTCCATTAATGGAAATGGTTCGTCTGAGTC  
 ATCTACGTTCCGAGTCAGGCTGTCACTCCTACTA - 3'



**Table 4: IGS4A-protein of SEQ ID NO: 2 and SEQ ID NO: 4 (without the three amino acids between brackets).**

5 (MSG) MEKLQNASWIYQQKLEDPFQKHLNSTEYLAFLCGPRRSHFFLPVSVVYVPIFVVGV  
 IGNVLVCLVILQHQAMKPTNYYLFSLAVSDLLVLLGMPLEVYEMWRNYPFLFGPGCY  
 FKTALFETVCFAISITTSVERYVAILHPFRAKLQSTRRALRILGIVWGFSLP  
 NTSIHGIKFHYFPNGSLVPGSATCTVIKPMWIYNFIIQVTSFLFYLLPMTVISVLYYLMA  
 LRLKKDKSLEADEGNANIQRPCRKSVNKMLFVLVLVFAICWAPFHIDRLFFSFVEEWSES  
 10 LAAVFNLVHVSGVFFYLSSAVNPIIYNLLSRRFQAAFQNVISSFKQWHSQHDPQLPPA  
 QRNIFLTECHFVELTEDIGPQFPCQSSMHNSHLPTALSSEQMSRTNYQSFHFNKT

**Table 5: IGS4B-protein of SEQ ID NO: 6 and SEQ ID NO: 8 (without the three amino acids between brackets).**

15 (MSG) MEKLQNASWIYQQKLEDPFQKHLNSTEYLAFLCGPRRSHFFLPVSVVYVPIFVVGV  
 IGNVLVCLVILQHQAMKPTNYYLFSLAVSDLLVLLGMPLEVYEMWRNYPFLFGPGCY  
 FKTALFETVCFAISITTSVERYVAILHPFRAKLQSTRRALRILGIVWGFSLP  
 NTSIHGIKFHYFPNGSLVPGSATCTVIKPMWIYNFIIQVTSFLFYLLPMTVISVLYYLMA  
 20 LRLKKDKSLEADEGNANIQRPCRKSVNKMLFVLVLVFAICWAPFHIDRLFFSFVEEWTES  
 LAAVFNLVHVSGVLFYLSSAVNPIIYNLLSRRFQAAFQNVISSFKQWHSQHDPQLPPA  
 QRNIFLTECHFVELTEDIGPQFLCQSSVHNSHLPTALSSEQMSRTNYQSFHFNKT

25 **Table 6: IGS4A-64-protein of SEQ ID NO: 10 and SEQ ID NO: 12 (without three amino acids between brackets).**

(MSG) MEKLQNASWIYQQKLEDPFQKHLNSTEYLAFLCGPRRSHFFLPVSVVYVPIFVVGV  
 IGNVLVCLVILQHQAMKPTNYYLFSLAVSDLLVLLGMPLEVYEMWRNYPFLFGPGCY  
 30 FKTALFETVCFAISITTSVERYVAILHPFRAKLQSTRRALRILGIVWGFSLP  
 NTSIHGIKFHYFPNGSLVPGSATCTVIKPMWIYNFIIQVTSFLFYLLPMTVISVLYYLMA  
 LRLKKDKSLEADEGNANIQRPCRKSVNKMLSLWRSGVNPWLCCSTSSMWCQSSST



**DESCRIPTION OF THE INVENTION****Definitions**

5       The following definitions are provided to facilitate understanding of certain terms used frequently herein.

"IGS4" refers, among others, to a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4 (IGS4A) and SEQ ID NO: 6 or SEQ ID NO: 8 (IGS4B), or a variant 10 thereof. Particularly preferred are polypeptides of IGS4B.

"Receptor Activity" or "Biological Activity of the Receptor" refers to the metabolic or physiologic function of said IGS4 including similar activities or improved activities or these activities with decreased undesirable side effects. Also included are antigenic and immunogenic activities of said IGS4.

15       "IGS4-gene" refers to a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 or variants thereof and/or their complements.

20       "Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of a Fab or other immunoglobulin expression library.

25       "Isolated" means altered "by the hand of man" from the natural state and/or separated from the natural environment. Thus, if an "isolated" composition or substance that occurs in nature has been "isolated", it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated", but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.


30       "Polynucleotide" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is a mixture of single-and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or 35 a mixture of single- and double-stranded regions. In addition, "polynucleotide" may also include triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications has been made to DNA and RNA; thus, "polynucleotide"



embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

5        "Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins, and/or to combinations thereof. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by  
10 natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well-described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying  
15 degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation,  
20 ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol; cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristylation, oxidation, proteolytic processing, phosphorylation, prenylation,  
25 racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993 and Wold, F., Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic  
30 Press, New York, 1983; Seifter et al., "Analysis for protein modifications and nonprotein cofactors", Meth. Enzymol. (1990) 182:626-646 and Rattan et al., "Protein Synthesis: Posttranslational Modifications and Aging", Ann. NY Acad. Sci. (1992) 663:48-62.

35        "Variant" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties such as essential biological, structural, regulatory or biochemical properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions




and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino 5 acid sequence by one or more substitutions, additions, and deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

10

"Identity" is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity" per se has an art-recognized meaning and can be calculated using published techniques. See, e.g.: (COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A.M., ed., Oxford University Press, New York, 15 1988; BIocomputing: INFORMATICS AND GENOME PROJECTS, Smith, D.W., ed.; Academic Press, New York, 1993; COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, 1987; and SEQUENCE ANALYSIS PRIMER, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to 20 measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H., and Lipton, D., SIAM J. Applied Math. (1988) 48:1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., SIAM J. Applied Math. (1988) 48:1073. Methods to 25 determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., Nucleic Acids Research (1984) 12(1):387), BLASTP, BLASTN, FASTA (Atschul, S.F. et al., J. Molec. Biol. (1990) 215:403). The word "homology" may substitute for the word "identity".

30

As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO: 1 is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five nucleotide differences per each 100 nucleotides of the reference 35 nucleotide sequence of SEQ ID NO: 1. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to any 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to any 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence, or in a number of nucleotides of up to any 5% of the total nucleotides in the



reference sequence there may be a combination of deletion, insertion and substitution. These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

Similarly, by a polypeptide having an amino acid sequence having at least, for example, 95% "identity" to a reference amino acid sequence of SEQ ID NO: 2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to any 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to any 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

## 20 Polypeptides of the Invention

In one aspect, the present invention relates to IGS4 polypeptides (or IGS4 proteins). The IGS4 polypeptides include the polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 and SEQ ID NO: 8 and the polypeptide having the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or deposit no. CBS102222, deposited on September 24, 1999 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands; as well as polypeptides comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8 and the polypeptide having the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands and polypeptides comprising the amino acid sequence which have at least 80% identity to that of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8 and/or the polypeptide having the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands over its entire length, and still more preferably at least 90% identity, and even still more preferably at least 95% identity to said amino acid sequences. Furthermore, those with at least 97%, in particular at least 99%, are highly preferred. Also included within IGS4 polypeptides are polypeptides having the amino acid sequence which has at least 80% identity to the polypeptide having the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8 or the polypeptide having the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or deposit



no.CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands over its entire length, and still more preferably at least 90% identity, and even still more preferably at least 95% identity to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8. Furthermore, those with at least 97%, in particular at least 99% are highly preferred. Preferably IGS4 polypeptides exhibit at least one biological activity of the receptor.

In an additional embodiment of the invention, the IGS4 polypeptides may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such 10 as multiple histidine residues, sequences which aid in detection such as antigenic peptide tags (such as the haemagglutinin (HA) tag), or an additional sequence for stability during recombinant production.

Fragments of the IGS4 polypeptides are also included in the invention. A fragment is a polypeptide having an amino acid sequence that is the same as part of, but not all of, the amino acid 15 sequence of the aforementioned IGS4 polypeptides. As with IGS4 polypeptides, fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20; 21-40, 41-60, 61-80, 81-100; and 101 to the end of IGS4 polypeptide. In this context "about" includes the particularly recited 20 ranges larger or smaller by several, 5, 4, 3, 2 or 1 amino acid at either extreme or at both extremes.

Preferred fragments include, for example, truncation polypeptides having the amino acid sequence of IGS4 polypeptides, except for deletion of a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus or deletion of two 25 continuous series of residues, one including the amino terminus and one including the carboxyl terminus. An example of a truncated polypeptide according to the present invention is the polypeptide of SEQ ID NO: 10 and SEQ ID NO: 12, which is encoded by the polynucleotide of SEQ ID NO: 9 respectively SEQ ID NO: 11. Also preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and 30 beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Other preferred fragments are biologically active fragments. Biologically active fragments are those that mediate receptor activity, including those with a similar activity or an improved activity, or with a decreased 35 undesirable activity. Also included are those that are antigenic or immunogenic in an animal, especially in a human.

Thus, the polypeptides of the invention include polypeptides having an amino acid sequence at least 80% identical to that of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8 and/or the



polypeptide having the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands, or fragments thereof with at least 80% identity to the corresponding fragment. Preferably, all of these polypeptide fragments retain the biological activity of the receptor, including antigenic 5 activity. Variants of the defined sequence and fragments also form part of the present invention. Preferred variants are those that vary from the referents by conservative amino acid substitutions – i.e., those that substitute a residue with another of like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are 10 variants in which several, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination.

With regard to the polypeptides of the present invention it was also found that they show a high affinity binding for neuromedin U, in particular for neuromedin U-8 (an oligopeptide of 8 amino acids), 15 neuromedin U-23 (an oligopeptide of 23 amino acids) and/or neuromedin U-25 (an oligopeptide of 25 amino acids). In the context of the present invention the term "high affinity" is understood as to describe a ligand binding showing log EC<sub>50</sub> values of at least below -6.00 (approx. 660 nM), preferably log EC<sub>50</sub> below -7.00 (approx. 55 nM), more preferably log EC<sub>50</sub> below -9.00 (approx. 500 pM to 1.2 nM), and most preferably log EC<sub>50</sub> below -10.00 (approx. 50-100 pM).

20

Two forms of the neuropeptide neuromedin U, neuromedin U-8 and neuromedin U-25, are described in the literature as uterus stimulating and hypertensive peptides (Minamino et al., 1985, Biochem. Biophys. Res. Commun. 130:1078-1085) being originally isolated from the porcine spinal cord. For neuromedin U-23, an oligopeptide of 23 amino acids, see for example: Okimura et al., Pept. Chem. 25 (1995), Vol. Date 1994, 32:321-324; Salmon et al., J. Biol. Chem. (2000), 275(7), 4549-4554. Neuromedin U (NMU) was subsequently isolated from a number of species, e.g. from rat (NMU-23), human (NMU-25), frog (NMU-25), dog (NMU-8 and NMU-25), rabbit (NMU-25), and chicken (NMU-25). Thus, Domin et al. described the characterization of neuromedin U like immunoreactivity in rat, porcine, guinea pig and human tissue extracts using a specific radioimmunoassay (1986, Biochem. Biophys. 30 Res. Commun. 140:1127-34). The primary structure of neuromedin U 23 from the rat ileum was established by Conlon et al. (1988, J. Neurochem. 51:988-991). Minamino et al. (1988, Biochem. Biophys. Res. Commun. 156:355-360) have isolated rat neuromedin U from the small intestine using mainly immunoaffinity chromatography and radioimmunoassay for pig neuromedin U-8, and the amino acid sequence of rat neuromedin U was determined by microsequence analysis and the structure was 35 confirmed by synthesis. Although the C-terminal heptapeptide amide structure of pig neuromedin U is completely conserved in rat neuromedin U, the remainder of the peptide reveals nine amino acid replacements and two amino acid deletions when compared to pig neuromedin U-25. The distribution, primary structure, and relative biological activity of neuromedin U has been determined also in the frog *Rana temporaria* by Domin et al. (1989, J. Biol. Chem. 264:20881-20885) showing that the entire




sequence was found to be an icosapentapeptide which displays marked sequence similarity to both porcine and rat neuromedin U. In a further study Domin et al.(1992, Regul. Pept. 41:1-8) have purified an avian homolog of neuromedin U from the chicken. Microsequence analysis characterized the peptide to be 25 amino acid residues long, and chicken neuromedin U showed marked sequence similarity with 5 the porcine peptide at its bioactive C-terminal region. Isolation, structural characterization and pharmacological activity of dog neuromedin U-25 was described by O'Harte et al. (1991 Peptides 12:11-15). Furthermore, for rabbit neuromedin U-25 it was found that it lacks conservation of a posttranslational processing site (Kage et al., 1991 Regul. Pept. 33:191-198); thus, in rabbit neuromedin U, the Arg16-Arg17 dibasic residue processing site that is found in pig and dog neuromedin U-25 is 10 replaced by Arg-Gly, but this potential monobasic processing site is not utilized by cleavage enzyme(s) in the intestine.

Among the species studied the 5 amino acids at the C-terminus of the peptide were found to be almost totally conserved, suggesting that this region is of major importance. Thus, mammalian 15 neuromedins share a common C-terminal sequence "-Phe-Leu-Phe-Arg-Pro-Arg-Asn-amide" which appears to be essential for its biological activities. NMU is distributed both in the gastrointestinal tract and the central nervous System (CNS). In the rat, the highest concentration of neuromedin (NMU) was found in the ileum, followed by the pituitary, hypothalamus, spinal cord, thyroid, and the genitourinary tract. Immunohistochemistry studies showed that NMU immunoreactivity in the gut was only found in 20 nerve fibers, mainly in the myenteric and submucous plexuses, and in the mucosa of all areas except stomach while no NMU immunoreactivity was found in endocrine cells. In the rat brain, NMU immunoreactivity was found in fibers widespread throughout the brain with the exception of the cerebellum. Human and rat genes encoding NMU precursor have been isolated. Both encode NMU at the C-terminus and other potential peptide products in the middle (Lo et al., 1992, J. Mol. Endocrinol. 25 6:1538-1544; Austin et al., 1995, J. Mol. Endocrinol. 14:157-169). High affinity NMU binding was characterized in rat uterus, and was shown to be sensitive to GTP- $\gamma$ S (Nandha et al., 1993, Endocrinology 133:482-486), suggesting that a receptor for NMU should be a G-protein coupled receptor. Nevertheless, the physiological role of NMU remains largely unknown. Neuromedin U can cause potent contraction of smooth muscle, increase arterial blood pressure, modify intestinal ion 30 transport, and at low doses stimulates the function and growth of the adrenal cortex. NMU was also shown to reduce the blood flow in superior enteric artery and portal vein while increase blood flow slightly in pancreatic tissue.

Furthermore, according to the international patent application WO 90/01330 the neuromedins U-8 and U-25 are described to be suitable in the treatment of disorders of the gastrointestinal tract, e.g. 35 being useful in the selective reduction of blood flow to the gastrointestinal tract, in the treatment of gastrointestinal bleeding and postprandial hypotension.

The IGS4 polypeptides of the present invention have been identified as a G-protein coupled receptor responsive to neuromedin U or ligands sufficiently similar thereto. Thus the IGS4 receptor, in



particular the IGS4B receptor, responsive to neuromedin U will greatly facilitate the understanding of the physiological mechanisms of neuromedin U and other ligands sufficiently similar thereto, as well as of related diseases.

5 The tissue distribution of the polypeptides of the present invention and the expression levels are shown in the Figures 5-8, from which the skilled artisan can estimate the localisation and relevance of expression. For instance, with regard to the tissue distribution of the polypeptides of the present invention it was found, e.g. by MTE (multiple tissue expression) analysis, Northern blot analysis and Quantitative RT-PCR expression analysis that the IGS4 polypeptides of the present invention particularly are brought to expression with a medium level (relative to expression in testis as 100% in MTE blot, or in spinal cord as 100% in Quantitative RT-PCR analysis, respectively) e.g. in brain, skeletal muscle, cerebellum, thymus, medulla, thyroid, trachea, thalamus, substantia nigra, corpus callosum, caudate nucleus, pons, nucleus accumbens, fetal brain and stomach; and with a relevant level (if being detectable by Quantitative RT-PCR analysis) e.g. in heart, lung, and prostate. For instance, expression 10 levels are considered to be medium if they amount at least 20% of the expression value found for the by far highest expression (set as 100%) in testis or spinal cord. For instance, expression levels are considered to be relevant if expression could be detected at least via Quantitative RT-PCR analysis. It will be appreciated that expression levels indicated for any organ are average values of expression levels in the specific tissues and cell types constituting the organ. Thus, if an expression level is just 15 found to be relevant with respect to an organ, this does not necessarily exclude medium or even high expression levels locally within a specific region, e.g. in a specific tissue and/or cell type, of the organ.

20

25 These results suggest that IGS4 polypeptides preferably play a role in the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), in the gastrointestinal system and/or in the cardiovascular system and/or in skeletal muscle and/or in the thyroid, and/or also in lung diseases, immunological diseases and disorders of the genitourinary system.

Thus, in a further embodiment the invention pertains also to an isolated IGS4 polypeptide comprising an amino acid sequence of a neuromedin receptor protein, preferably of a mammalian 30 neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25. Particularly, the isolated IGS4 polypeptide comprising an amino acid sequence of a neuromedin receptor protein, is a protein exhibiting expression (being at least detectable via Northern and/or MTE and/or Quantitative RT-PCR analysis) in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, 35 thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea. In a variant of this embodiment the invention pertains to an isolated IGS4 polypeptide comprising an amino acid sequence of a neuromedin receptor protein, preferably of a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, said protein exhibiting



expression (being at least detectable via Northern and/or MTE and/or Quantitative RT-PCR analysis) in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea, and said amino acid sequence being selected from the group of 5 amino acid sequence as already defined supra.

The IGS4 polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. 10 Methods for preparing such polypeptides are well known in the art.

### Polynucleotides of the Invention

A further aspect of the invention relates to IGS4 polynucleotides. IGS4 polynucleotides include 15 isolated polynucleotides which encode the IGS4 polypeptides (including IGS4A and IGS4B) and fragments, and polynucleotides closely related thereto. More specifically, the IGS4 polynucleotide of the invention includes a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 encoding a IGS4A polypeptide of SEQ ID NO: 2 or of SEQ ID NO: 4 and a IGS4B polypeptide of SEQ ID NO: 6 or of SEQ ID NO: 8 respectively, 20 polynucleotides having the particular sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 and polynucleotides which essentially correspond to the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands.

25 IGS4 polynucleotides further include polynucleotides comprising a nucleotide sequence that has at least 80% identity over its entire length to a nucleotide sequence encoding the IGS4 polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8, a polynucleotide comprising a nucleotide sequence that is at least 80% identical to that of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 over its entire length and a polynucleotide which essentially correspond to the DNA 30 insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands.

In this regard, polynucleotides with at least 90% identity are particularly preferred, and those with 35 at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred and those with at least 98-99% are most highly preferred, with at least 99% being the most preferred. Also included under IGS4 polynucleotides are a nucleotide sequence which has sufficient identity to a nucleotide sequence contained in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 or to the DNA insert contained in the deposit no. CBS102221 or in the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands to hybridize under conditions useable



for amplification or for use as a probe or marker. The invention also provides polynucleotides which are complementary to such IGS4 polynucleotides.

IGS4 of the invention is structurally related to other proteins of the G-protein coupled receptor family, as shown by the results of BLAST searches in the public databases. The amino acid sequence of Table 1 (SEQ ID NO: 2) has about 46 % identity (using BLAST, Altschul S.F. et al. [1997], Nucleic Acids Res. 25:3389-3402) over most of its length (316 amino acid residues) with a human orphan G-protein coupled receptor (Accession # O43664, Tan et al., Genomics 52(2):223-229 (1998). There is 27 % homology (over amino acid residues 61-349 ) to the rat neurotensin 1 receptor (Accession # P20789 10 Tanaka K. et al, Neuron 4:847-854 (1990)). The nucleotide sequence of Table 1 (SEQ ID NO: 1) is 63 % identical to an orphan G-protein coupled receptor over nucleotide residues 120-864 (Accession # AF044600, corresponding with the protein sequence O43664). Furthermore, there is 53 % identity to the human growth hormone secretagogue receptor over residues 94-1137 (Howard A.D. et al, Science 273:974-977(1996)). Thus, IGS4 polypeptides and polynucleotides of the present invention are 15 expected to have, inter alia, similar biological functions/properties to their homologous polypeptides and polynucleotides, and their utility is obvious to anyone skilled in the art.

Polynucleotides of the invention can be obtained from natural sources such as genomic DNA. In particular, degenerated PCR primers can be designed that encode conserved regions within a particular 20 GPCR gene subfamily. PCR amplification reactions on genomic DNA or cDNA using the degenerate primers will result in the amplification of several members (both known and novel) of the gene family under consideration (the degenerated primers must be located within the same exon, when a genomic template is used). (Libert et al., Science, 1989, 244: 569-572). Polynucleotides of the invention can also be synthesized using well-known and commercially available techniques (e.g. F.M. Ausubel et al, 2000, 25 Current Protocols in Molecular Biology).

The nucleotide sequence encoding the IGS4 polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8 may be identical to the polypeptide encoding sequence contained in SEQ ID NO: 1 (nucleotide number 55 to 1299) or SEQ ID NO: 3 (nucleotide number 64 to 1299), or SEQ ID NO: 30 5 (nucleotide number 55 to 1299) or SEQ ID NO: 7 (nucleotide number 64 to 1299) respectively, or it may be a different nucleotide sequence, which as a result of the redundancy (degeneracy) of the genetic code might also show alterations compared to the polypeptide encoding sequence contained in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7, but also encodes the polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8, respectively.

35

In a further embodiment the invention pertains to an isolated nucleotide sequence encoding an IGS4 neuromedin receptor protein, preferably encoding a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25. Particularly, the isolated nucleotide sequence encodes an IGS4



neuromedin receptor protein which is a protein exhibiting expression (being at least detectable via Northern and/or MTE and/or Quantitative RT-PCR analysis) in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea. In a 5 variant of this embodiment the invention pertains to an isolated nucleotide sequence encoding an IGS4 neuromedin receptor protein, preferably encoding a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, said protein exhibiting expression (being at least detectable via Northern and/or MTE and/or Quantitative RT-PCR analysis) in brain, skeletal muscle, cerebellum, testis, 10 corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea, and said nucleotide sequence being selected from the group of nucleotide sequences as already defined supra.

When the polynucleotides of the invention are used for the recombinant production of the IGS4 15 polypeptide, the polynucleotide may include the coding sequence for the mature polypeptide or a fragment thereof, by itself; the coding sequence for the mature polypeptide or fragment in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this 20 aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al., Proc. Natl. Acad. Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

25

Further preferred embodiments are polynucleotides encoding IGS4 variants comprising the amino acid sequence of the IGS4 polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8 in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acid residues are substituted, deleted or added, in any combination.

30

The polynucleotides of the invention can be engineered using methods generally known in the art in order to alter IGS4-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to 35 engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create amino acid substitutions, create new restriction sites, alter modification (e.g. glycosylation or phosphorylation) patterns, change codon preference, produce splice variants, and so forth.



The present invention further relates to polynucleotides that hybridize to the herein above-described sequences. In this regard, the present invention especially relates to polynucleotides which hybridize under stringent conditions to the polynucleotides described above. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 80%, and preferably at least 5 90%, and more preferably at least 95%, yet even more preferably at least 97%, in particular at least 99% identity between the sequences.

Polynucleotides of the invention, which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 or a fragment thereof, may be used as hybridization probes for cDNA and genomic DNA, to isolate full-length cDNAs and genomic clones encoding IGS4 and to isolate cDNA and genomic clones of other genes (including genes encoding homologs and orthologs from species other than human) that have a high sequence similarity to the IGS4 gene. People skilled in the art are well aware of such hybridization techniques. Typically these nucleotide sequences are 80% identical, preferably 90% identical, more preferably 95% identical to that of the referent. The probes generally will comprise at least 5 nucleotides, and preferably at least 8 nucleotides, and more preferably at least 10 nucleotides, yet even more preferably at least 12 nucleotides, in particular at least 15 nucleotides. Most preferred, such probes will have at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will range between 30 and 50 nucleotides.

20

One embodiment, to obtain a polynucleotide encoding the IGS4 polypeptide, including homologs and orthologs from species other than human, comprises the steps of screening an appropriate library under stringent hybridization conditions with a labeled probe having the SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 or a fragment thereof, and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to those of skill in the art. Stringent hybridization conditions are as defined above or alternatively conditions under overnight incubation at 42 °C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate (w/v), and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 30 0.1xSSC at about 65°C.

The polynucleotides and polypeptides of the present invention may be used as research reagents and materials for discovery of treatments and diagnostics to animal and human disease.

35

#### Vectors, Host Cells, Expression

The present invention also relates to vectors which comprise a polynucleotide or polynucleotides of the present invention, and host cells which are genetically engineered with vectors of the invention and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation



systems can also be used to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., BASIC METHODS IN MOLECULAR BIOLOGY (1986) and Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) such as calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells; fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used. Such systems include, among others, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL (supra).

30

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the desired polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals, i.e. derived from a different species.

35

If the IGS4 polypeptide is to be expressed for use in screening assays, generally, it is preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. In case the affinity or functional activity of the IGS4 polypeptide is modified by receptor activity modifying proteins (RAMP), coexpression of the relevant RAMP most likely



at the surface of the cell is preferred and often required. Also in this event harvesting of cells expressing the IGS4 polypeptide and the relevant RAMP prior to use in screening assays is required. If the IGS4 polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide; if produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

- 5      Membranes expressing the IGS4 polypeptide can be recovered by methods that are well known to a person skilled in the art. In general, such methods include harvesting of the cells expressing the IGS4 polypeptide and homogenization of the cells by a method such as, but not limited to, pottering. The membranes may be recovered by washing the suspension one or several times.
- 10     IGS4 polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well-known techniques for refolding 15 proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

#### Diagnostic Assays

- 20     This invention also relates to the use of IGS4 polynucleotides for use as diagnostic reagents. Detection of a mutated form of the IGS4 gene associated with a dysfunction will provide a diagnostic tool that can add to or define a diagnosis of a disease or susceptibility to a disease which results from under-expression, over-expression or altered expression of IGS4. Also in this event co-expression of relevant receptor activity modifying proteins can be required to obtain diagnostic assays of desired quality.
- 25     Individuals carrying mutations in the IGS4 gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may 30 be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled IGS4 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures.

35     DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers et al., Science (1985) 230:1242. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method. See Cotton et al., Proc. Natl. Acad. Sci. USA (1985) 85: 4397-4401. In another embodiment, an array of



oligonucleotide probes comprising the IGS4 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability. (See for example: M.Chee et al., Science, Vol 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to PNS, psychiatric and CNS disorders, including schizophrenia, episodic paroxysmal anxiety (EPA) disorders such as obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), phobia and panic, major depressive disorder, bipolar disorder, Parkinson's disease, general anxiety disorder, autism, delirium, multiple sclerosis, Alzheimer disease/dementia and other neurodegenerative diseases, severe mental retardation, dyskinesias, Huntington's disease, Tourett's syndrome, tics, tremor, dystonia, spasms, anorexia, bulimia, stroke, addiction/dependency/craving, sleep disorder, epilepsy, migraine; attention deficit/hyperactivity disorder (ADHD); cardiovascular diseases, including heart failure, angina pectoris, arrhythmias, myocardial infarction, cardiac hypertrophy, hypotension, hypertension – e.g. essential hypertension, renal hypertension, or pulmonary hypertension, thrombosis, arteriosclerosis, cerebral vasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral infarction, peripheral vascular disease, Raynaud's disease, kidney disease – e.g. renal failure; dyslipidemias; obesity; emesis; gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), motility disorders and conditions of delayed gastric emptying, such as post operative or diabetic gastroparesis, and diabetes, ulcers – e.g. gastric ulcer; diarrhoea; other diseases including osteoporosis; inflammations; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; chemotherapy induced injury; tumor invasion; immune disorders; urinary retention; asthma; allergies; arthritis; benign prostatic hypertrophy; endotoxin shock; sepsis; complication of diabetes mellitus; and gynaecological disorders, through detection of mutation in the IGS4 gene by the methods described. According to the present invention, the diagnostic assays offer in particular a process for diagnosing or determining a susceptibility to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system.

In addition, PNS, psychiatric and CNS disorders, including schizophrenia, episodic paroxysmal anxiety (EPA) disorders such as obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), phobia and panic, major depressive disorder, bipolar disorder, Parkinson's disease, general anxiety disorder, autism, delirium, multiple sclerosis, Alzheimer disease/dementia and other neurodegenerative diseases, severe mental retardation, dyskinesias, Huntington's disease, Tourett's syndrome, tics, tremor, dystonia, spasms, anorexia, bulimia, stroke, addiction/dependency/craving, sleep disorder, epilepsy, migraine; attention deficit/hyperactivity disorder (ADHD); cardiovascular



diseases, including heart failure, angina pectoris, arrhythmias, myocardial infarction, cardiac hypertrophy, hypotension, hypertension – e.g. essential hypertension, renal hypertension, or pulmonary hypertension, thrombosis, arteriosclerosis, cerebral vasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral infarction, peripheral vascular disease, Raynaud's disease, kidney disease – e.g. 5 renal failure; dyslipidemias; obesity; emesis; gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), motility disorders and conditions of delayed gastric emptying, such as post operative or diabetic gastroparesis, and diabetes, ulcers – e.g. gastric ulcer; diarrhoea; other diseases including osteoporosis; inflammations; infections such as bacterial, fungal, protozoan and viral infections, particularly infections 10 caused by HIV-1 or HIV-2; pain; cancers; chemotherapy induced injury; tumor invasion; immune disorders; urinary retention; asthma; allergies; arthritis; benign prostatic hypertrophy; endotoxin shock; sepsis; complication of diabetes mellitus; and gynaecological disorders, can be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of the IGS4 polypeptide or IGS4 mRNA. In particular disorders of the nervous system, including the 15 central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also lung diseases, immunological diseases and disorders of the genitourinary system can be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of the IGS4 polypeptide or IGS4 mRNA. Decreased or 20 increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as an IGS4, in a sample derived from a host are well known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis 25 and ELISA assays.

In another aspect, the present invention relates to a diagnostic kit for a disease or susceptibility to a disease, particularly PNS, psychiatric and CNS disorders, including schizophrenia, episodic paroxysmal anxiety (EPA) disorders such as obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), phobia and panic, major depressive disorder, bipolar disorder, Parkinson's disease, general anxiety disorder, autism, delirium, multiple sclerosis, Alzheimer disease/dementia and other neurodegenerative diseases, severe mental retardation, dyskinesias, Huntington's disease, Tourette's syndrome, tics, tremor, dystonia, spasms, anorexia, bulimia, stroke, addiction/dependency/craving, sleep disorder, epilepsy, migraine; attention deficit/hyperactivity disorder 30 (ADHD); cardiovascular diseases, including heart failure, angina pectoris, arrhythmias, myocardial infarction, cardiac hypertrophy, hypotension, hypertension – e.g. essential hypertension, renal hypertension, or pulmonary hypertension, thrombosis, arteriosclerosis, cerebral vasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral infarction, peripheral vascular disease, Raynaud's disease, kidney disease – e.g. renal failure; dyslipidemias; obesity; emesis; gastrointestinal 35



- disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), motility disorders and conditions of delayed gastric emptying, such as post operative or diabetic gastroparesis, and diabetes, ulcers – e.g. gastric ulcer; diarrhoea; other diseases including osteoporosis; inflammations; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; chemotherapy induced injury; tumor invasion; immune disorders; urinary retention; asthma; allergies; arthritis; benign prostatic hypertrophy; endotoxin shock; sepsis; complication of diabetes mellitus; and gynaecological disorders, which comprises:
- (a) an IGS4 polynucleotide, preferably the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7, or a fragment thereof; and/or
- (b) a nucleotide sequence complementary to that of (a); and/or
- (c) an IGS4 polypeptide, preferably the polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or of SEQ ID NO: 8, or a fragment thereof; and/or
- (d) an antibody to an IGS4 polypeptide, preferably to the polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or of SEQ ID NO: 8; and/or
- (e) a RAMP polypeptide required for the relevant biological or antigenic properties of an IGS4 polypeptide

It will be appreciated that in any such kit, (a), (b), (c) (d) or (e) may comprise a substantial component.

Preferably the present invention relates to a diagnostic kit for diagnosing or determining a disease or a susceptibility to a disease of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), a disease of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also lung diseases, immunological diseases and disorders of the genitourinary system.

25

#### **Chromosome Assays**

The nucleotide sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).



The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.



**Antibodies**

The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them if required together with relevant RAMP's, may also be used as immunogens to produce antibodies 5 immunospecific for the IGS4 polypeptides. The term "immunospecific" means that the antibodies have substantiall greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against the IGS4 polypeptides may be obtained by administering the 10 polypeptides or epitope-bearing frgments, analogs or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique, which provides antibodies produced by continuous cell line cultures, may be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Naure (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., Immunology Today (1983) 4:72) and the EBV-hybridoma technique 15 (Cole et al., MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).

The above-described antibodies may be employed to isolate or to identify clones expressing the 20 polypeptide or to purify the polypeptides by affinity chromatography.

Antibodies against IGS4 polypeptides as such, or against IGS4 polypeptide-RAMP complexes, may also be employed to treat PNS, psychiatric and CNS disorders, including schizophrenia, episodic paroxysmal anxiety (EPA) disorders such as obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), phobia and panic, major depressive disorder, bipolar disorder, Parkinson's disease, general 25 anxiety disorder, autism, delirium, multiple sclerosis, Alzheimer disease/dementia and other neurodegenerative diseases, severe mental retardation, dyskinesias, Huntington's disease, Tourett's syndrome, tics, tremor, dystonia, spasms, anorexia, bulimia, stroke, addiction/dependency/craving, sleep disorder, epilepsy, migraine; attention deficit/hyperactivity disorder (ADHD); cardiovascular diseases, including heart failure, angina pectoris, arrhythmias, myocardial infarction, cardiac 30 hypertrophy, hypotension, hypertension – e.g. essential hypertension, renal hypertension, or pulmonary hypertension, thrombosis, arteriosclerosis, cerebral vasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral infarction, peripheral vascular disease, Raynaud's disease, kidney disease – e.g. renal failure; dyslipidemias; obesity; emesis; gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), motility 35 disorders and conditions of delayed gastric emptying, such as post operative or diabetic gastroparesis, and diabetes, ulcers – e.g. gastric ulcer; diarrhoea; other diseases including osteoporosis; inflammations; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; chemotherapy induced injury; tumor invasion; immune disorders; urinary retention; asthma; allergies; arthritis; benign prostatic hypertrophy; endotoxin shock;



sepsis; complication of diabetes mellitus; and gynaecological disorders, among others. Preferably the antibodies of the present invention may be used to treat disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to treat lung diseases, immunological diseases and disorders of the genitourinary system.

### Animals

Another aspect of the invention relates to non-human animal-based systems which act as models for disorders arising from aberrant expression or activity of IGS4. Non-human animal-based model systems may also be used to further characterize the activity of the IGS4 gene. Such systems may be utilized as part of screening strategies designed to identify compounds which are capable to treat IGS4 based disorders such as PNS, psychiatric and CNS disorders, including schizophrenia, episodic paroxysmal anxiety (EPA) disorders such as obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), phobia and panic, major depressive disorder, bipolar disorder, Parkinson's disease, general anxiety disorder, autism, delirium, multiple sclerosis, Alzheimer disease/dementia and other neurodegenerative diseases, severe mental retardation, dyskinesias, Huntington's disease, Tourett's syndrome, tics, tremor, dystonia, spasms, anorexia, bulimia, stroke, addiction/dependency/craving, sleep disorder, epilepsy, migraine; attention deficit/hyperactivity disorder (ADHD); cardiovascular diseases, including heart failure, angina pectoris, arrhythmias, myocardial infarction, cardiac hypertrophy, hypotension, hypertension – e.g. essential hypertension, renal hypertension, or pulmonary hypertension, thrombosis, arteriosclerosis, cerebral vasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral infarction, peripheral vascular disease, Raynaud's disease, kidney disease – e.g. renal failure; dyslipidemias; obesity; emesis; gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), motility disorders and conditions of delayed gastric emptying, such as post operative or diabetic gastroparesis, and diabetes, ulcers – e.g. gastric ulcer; diarrhoea; other diseases including osteoporosis; inflammations; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; chemotherapy induced injury; tumor invasion; immune disorders; urinary retention; asthma; allergies; arthritis; benign prostatic hypertrophy; endotoxin shock; sepsis; complication of diabetes mellitus; and gynaecological disorders. In particular, the systems may be utilized as part of screening strategies designed to identify compounds which are capable in particular to treat IGS4 based disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to treat lung diseases, immunological diseases and disorders of the genitourinary system. In this way the animal-based models may be used to identify pharmaceutical compounds, therapies and interventions which may be effective in treating disorders of aberrant expression or



activity of IGS4. In addition such animal models may be used to determine the LD<sub>50</sub> and the ED<sub>50</sub> in animal subjects. These data may be used to determine the *in vivo* efficacy of potential IGS4 disorder treatments.

5 Animal-based model systems of IGS4 based disorders, based on aberrant IGS4 expression or activity, may include both non-recombinant animals as well as recombinantly engineered transgenic animals.

10 Animal models for IGS4 disorders may include, for example, genetic models. Animal models exhibiting IGS4 based disorder-like symptoms may be engineered by utilizing, for example, IGS4 sequences such as those described, above, in conjunction with techniques for producing transgenic animals that are well known to persons skilled in the art. For example, IGS4 sequences may be introduced into, and overexpressed and/or misexpressed in, the genome of the animal of interest, or, if endogenous IGS4 sequences are present, they may either be overexpressed, misexpressed, or, alternatively, may be disrupted in order to underexpress or inactivate IGS4 gene expression.

15

In order to overexpress or misexpress a IGS4 gene sequence, the coding portion of the IGS4 gene sequence may be ligated to a regulatory sequence which is capable of driving high level gene expression or expression in a cell type in which the gene is not normally expressed in the animal type of interest. Such regulatory regions will be well known to those skilled in the art, and may be utilized in the 20 absence of undue experimentation.

25 For underexpression of an endogenous IGS4 gene sequence, such a sequence may be isolated and engineered such that when reintroduced into the genome of the animal of interest, the endogenous IGS4 gene alleles will be inactivated, or "knocked-out". Preferably, the engineered IGS4 gene sequence is introduced via gene targeting such that the endogenous IGS4 sequence is disrupted upon integration of the engineered IGS4 gene sequence into the animal's genome. Gene targeting is discussed, below, in this section.

30 Animals of any species, including, but not limited to, mice, rats, rabbits, squirrels, guinea-pigs, pigs, micro-pigs, goats, and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate animal models of IGS4 related disorders.

35 Any technique known in the art may be used to introduce a IGS4 transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to pronuclear microinjection (Hoppe, P.C. and Wagner, T.E., 1989, U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152, 1985); gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321, 1989,); electroporation of embryos (Lo, Mol. Cell. Biol. 3:1803-1B14, 1983); and sperm-mediated gene transfer (Lavitrano et al.,



Cell 57:717-723, 1989); etc. For a review of such techniques, see Gordon, Transgenic Animals, Intl. Rev. Cytol. 115:171-229, 1989, which is incorporated by reference herein in its entirety.

The present invention provides for transgenic animals that carry the IGS4 transgene in all their  
5 cells, as well as animals which carry the transgene in some, but not all their cells, i.e., mosaic animals.  
(See, for example, techniques described by Jakobovits, Curr. Biol. 4:761-763, 1994) The transgene may  
be integrated as a single transgene or in concatamers, e.g., head-to-head tandems or head-to-tail  
tandems. The transgene may also be selectively introduced into and activated in a particular cell type by  
following, for example, the teaching of Lasko et al. (Lasko, M. et al., Proc. Natl. Acad. Sci. USA 89:6232-  
10 6236, 1992).

The regulatory sequences required for such a cell-type specific activation will depend upon the  
particular cell type of interest, and will be apparent to those of skill in the art.

15 When it is desired that the IGS4 transgene be integrated into the chromosomal site of the  
endogenous IGS4 gene, gene targeting is preferred. Briefly, when such a technique is to be utilized,  
vectors containing some nucleotide sequences homologous to the endogenous IGS4 gene of interest  
(e.g., nucleotide sequences of the mouse IGS4 gene) are designed for the purpose of integrating, via  
homologous recombination with chromosomal sequences, into and disrupting the function of, the  
20 nucleotide sequence of the endogenous IGS4 gene or gene allele. The transgene may also be  
selectively introduced into a particular cell type, thus inactivating the endogenous gene of interest in only  
that cell type, by following, for example, the teaching of Gu et al. (Gu, H. et al., Science 265:103-106,  
1994). The regulatory sequences required for such a cell-type specific inactivation will depend upon the  
particular cell type of interest, and will be apparent to those of skill in the art.

25

Once transgenic animals have been generated, the expression of the recombinant IGS4 gene  
and protein may be assayed utilizing standard techniques. Initial screening may be accomplished by  
Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the  
transgene has taken place. The level of mRNA expression of the IGS4 transgene in the tissues of the  
30 transgenic animals may also be assessed using techniques which include but are not limited to Northern  
blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and RT-PCR.  
Samples of target gene-expressing tissue, may also be evaluated immunocytochemically using  
antibodies specific for the target gene transgene product of interest. The IGS4 transgenic animals that  
express IGS4 gene mRNA or IGS4 transgene peptide (detected immunocytochemically, using  
35 antibodies directed against target gene product epitopes) at easily detectable levels may then be further  
evaluated to identify those animals which display characteristic IGS4 based disorder symptoms.

Once IGS4 transgenic founder animals are produced (i.e., those animals which express IGS4  
proteins in cells or tissues of interest, and which, preferably, exhibit symptoms of IGS4 based disorders),



they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound IGS4 transgenics that express the IGS4 transgene of interest at higher levels because of the effects of additive expression of each IGS4 transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the possible need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; breeding animals to different inbred genetic backgrounds so as to examine effects of modifying alleles on expression of the IGS4 transgene and the development of IGS4-like symptoms. One such approach is to cross the IGS4 transgenic founder animals with a wild type strain to produce an F1 generation that exhibits IGS4 related disorder-like symptoms, such as those described above. The F1 generation may then be inbred in order to develop a homozygous line, if it is found that homozygous target gene transgenic animals are viable.

15           **Vaccines**

Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises administering to (for example by inoculation) the mammal the IGS4 polypeptide, or a fragment thereof, if required together with a RAMP polypeptide, adequate to produce antibody and/or T cell immune response to protect said animal from PNS, psychiatric and CNS disorders, including schizophrenia, episodic paroxysmal anxiety (EPA) disorders such as obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), phobia and panic, major depressive disorder, bipolar disorder, Parkinson's disease, general anxiety disorder, autism, delirium, multiple sclerosis, Alzheimer disease/dementia and other neurodegenerative diseases, severe mental retardation, dyskinesias, Huntington's disease, Touretts syndrome, tics, tremor, dystonia, spasms, anorexia, bulimia, stroke, addiction/dependency/craving, sleep disorder, epilepsy, migraine; attention deficit/hyperactivity disorder (ADHD); cardiovascular diseases, including heart failure, angina pectoris, arrhythmias, myocardial infarction, cardiac hypertrophy, hypotension, hypertension – e.g. essential hypertension, renal hypertension, or pulmonary hypertension, thrombosis, arteriosclerosis, cerebral vasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral infarction, peripheral vascular disease, Raynaud's disease, kidney disease – e.g. renal failure; dyslipidemias; obesity; emesis; gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), motility disorders and conditions of delayed gastric emptying, such as post operative or diabetic gastroparesis, and diabetes, ulcers – e.g. gastric ulcer; diarrhoea; other diseases including osteoporosis; inflammations; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; chemotherapy induced injury; tumor invasion; immune disorders; urinary retention; asthma; allergies; arthritis; benign prostatic hypertrophy; endotoxin shock; sepsis; complication of diabetes mellitus; and gynaecological disorders, among others. Yet another aspect of the invention relates to a method of inducing



immunological response in a mammal which comprises delivering the IGS4 polypeptide via a vector directing expression of the IGS4 polynucleotide in vivo in order to induce such an immunological response to produce antibody to protect said animal from diseases. In particular the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the 5 mammal with the IGS4 polypeptide, or a fragment thereof, if required together with a RAMP polypeptide, adequate to produce antibody and/or T cell immune response to protect said animal from disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also from lung diseases, immunological diseases and disorders of 10 the genitourinary system.

A further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to an IGS4 polypeptide wherein the composition comprises an IGS4 polypeptide or IGS4 gene. Such 15 immunological/vaccine formulations (compositions) may be either therapeutic immunological/vaccine formulations or prophylactic immunological/vaccine formulations. The vaccine formulation may further comprise a suitable carrier. Since the IGS4 polypeptide may be broken down in the stomach, it is preferably administered parenterally (including subcutaneous, intramuscular, intravenous, intradermal etc. injection). Formulations suitable for parenteral administration include aqueous and non-aqueous 20 sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior 25 to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

#### Screening Assays

30 The IGS4 polypeptide of the present invention may be employed in a screening process for compounds which bind the receptor and which activate (agonists) or inhibit activation of (antagonists) the receptor polypeptide of the present invention. Thus, polypeptides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free 35 preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics.

IGS4 polypeptides are responsible for biological functions, including pathologies. Accordingly, it is desirable to find compounds and drugs which stimulate IGS4 on the one hand and which can inhibit the



function of IGS4 on the other hand. In general, agonists are employed for therapeutic and prophylactic purposes for such conditions as PNS, psychiatric and CNS disorders, including schizophrenia, episodic paroxysmal anxiety (EPA) disorders such as obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), phobia and panic, major depressive disorder, bipolar disorder, Parkinson's disease, general anxiety disorder, autism, delirium, multiple sclerosis, Alzheimer disease/dementia and other neurodegenerative diseases, severe mental retardation, dyskinesias, Huntington's disease, Tourett's syndrome, tics, tremor, dystonia, spasms, anorexia, bulimia, stroke, addiction/dependency/craving, sleep disorder, epilepsy, migraine; attention deficit/hyperactivity disorder (ADHD); cardiovascular diseases, including heart failure, angina pectoris, arrhythmias, myocardial infarction, cardiac hypertrophy, hypotension, hypertension – e.g. essential hypertension, renal hypertension, or pulmonary hypertension, thrombosis, arteriosclerosis, cerebral vasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral infarction, peripheral vascular disease, Raynaud's disease, kidney disease – e.g. renal failure; dyslipidemias; obesity; emesis; gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), motility disorders and conditions of delayed gastric emptying, such as post operative or diabetic gastroparesis, and diabetes, ulcers – e.g. gastric ulcer; diarrhoea; other diseases including osteoporosis; inflammations; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; chemotherapy induced injury; tumor invasion; immune disorders; urinary retention; asthma; allergies; arthritis; benign prostatic hypertrophy; endotoxin shock; sepsis; complication of diabetes mellitus; and gynaecological disorders.

Antagonists may be employed for a variety of therapeutic and prophylactic purposes for such conditions as PNS, psychiatric and CNS disorders, including schizophrenia, episodic paroxysmal anxiety (EPA) disorders such as obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), phobia and panic, major depressive disorder, bipolar disorder, Parkinson's disease, general anxiety disorder, autism, delirium, multiple sclerosis, Alzheimer disease/dementia and other neurodegenerative diseases, severe mental retardation, dyskinesias, Huntington's disease, Tourett's syndrome, tics, tremor, dystonia, spasms, anorexia, bulimia, stroke, addiction/dependency/craving, sleep disorder, epilepsy, migraine; attention deficit/hyperactivity disorder (ADHD); cardiovascular diseases, including heart failure, angina pectoris, arrhythmias, myocardial infarction, cardiac hypertrophy, hypotension, hypertension – e.g. essential hypertension, renal hypertension, or pulmonary hypertension, thrombosis, arteriosclerosis, cerebral vasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral infarction, peripheral vascular disease, Raynaud's disease, kidney disease – e.g. renal failure; dyslipidemias; obesity; emesis; gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), motility disorders and conditions of delayed gastric emptying, such as post operative or diabetic gastroparesis, and diabetes, ulcers – e.g. gastric ulcer; diarrhoea; other diseases including osteoporosis; inflammations; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; chemotherapy induced injury; tumor invasion; immune disorders; urinary retention; asthma; allergies; arthritis; benign prostatic hypertrophy; endotoxin shock; sepsis; complication of diabetes mellitus; and



gynaecological disorders. Particularly, the present invention may be employed in a screening process for compounds which bind the receptor and which activate (agonists) or inhibit activation of (antagonists) the IGS4 neuromedin receptor protein, preferably the mammalian IGS4 neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for 5 neuromedin U-23 and/or for neuromedin U-25. These screening assays are particularly suitable for screening compounds which are effective with regard to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system.

10

In general, such screening procedures involve producing appropriate cells, which express the receptor polypeptide of the present invention on the surface thereof and, if essential co-expression of RAMP's at the surface thereof. Such cells include cells from mammals, yeast, Drosophila or E. coli. Cells expressing the receptor (or cell membrane containing the expressed receptor) are then contacted 15 with a test compound to observe binding, or stimulation or inhibition of a functional response.

One screening technique includes the use of cells which express the receptor of this invention (for example, transfected CHO cells) in a system which measures extracellular pH, intracellular pH, or intracellular calcium changes caused by receptor activation. In this technique, compounds may be 20 contacted with cells expressing the receptor polypeptide of the present invention. A second messenger response, e.g., signal transduction, pH changes, or changes in calcium level, is then measured to determine whether the potential compound activates or inhibits the receptor.

Another method involves screening for receptor inhibitors by determining modulation of a 25 receptor-mediated signal, such as cAMP accumulation and/or adenylate cyclase activity. Such a method involves transfecting an eukaryotic cell with the receptor of this invention to express the receptor on the cell surface. The cell is then exposed to an agonist to the receptor of this invention in the presence of a potential antagonist. If the potential antagonist binds the receptor, and thus inhibits receptor binding, the agonist-mediated signal will be modulated.

30

Another method for detecting agonists or antagonists for the receptor of the present invention is the yeast-based technology as described in U.S. Patent 5,482,835, incorporated by reference herein.

The assays may simply test binding of a candidate compound wherein adherence to the cells 35 bearing the receptor is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor. Further, these assays may test whether the candidate compound results in a signal generated by activation of the receptor, using detection systems appropriate to the cells bearing the receptor at their surfaces. Inhibitors of activation



are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed.

Thus candidate compounds may be screened which show ligand binding to the IGS4 receptors of

5 the present invention. In the context of the present invention the term "ligand binding" is understood as to describe compounds with affinity to the IGS4 receptors showing log EC<sub>50</sub> values of at least below –6.00 (approx. 660 nM), preferably log EC<sub>50</sub> below –7.00 (approx. 55 nM), more preferably log EC<sub>50</sub> below –9.00 (approx. 500 pM to 1.2 nM), and most preferably log EC<sub>50</sub> below –10.00 (approx. 50-100 pM).

10

Thus in one aspect the invention concerns a method of determining whether a substance is a potential ligand of IGS4 receptor comprising

(a) contacting cells expressing one of the IGS4 neuromedin receptors defined supra or one of the receptors of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8, or contacting a receptor membrane preparation comprising one of said IGS4 neuromedin receptors defined supra or one of the receptors of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8 with labeled neuromedin U in the presence and in the absence of the substance; and

(b) measuring the binding of neuromedin U to IGS4.

20 Further, the assays may simply comprise the steps of mixing a candidate compound with a solution containing an IGS4 polypeptide to form a mixture, measuring the IGS4 activity in the mixture, and comparing the IGS4 activity of the mixture to a standard.

The IGS4 cDNA, protein and antibodies to the protein may also be used to configure assays for 25 detecting the effect of added compounds on the production of IGS4 mRNA and protein in cells. For example, an ELISA may be constructed for measuring secreted or cell associated levels of IGS4 protein using monoclonal and polyclonal antibodies by standard methods known in the art, and this can be used to discover agents which may inhibit or enhance the production of IGS4 (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues. Standard methods for conducting 30 screening assays are well known in the art.

Examples of potential IGS4 antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligand of the IGS4, e.g., a fragment of the ligand, or small molecules which bind to the receptor but do not elicit a response, so that the activity of the receptor is 35 prevented.

Thus in another aspect, the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for IGS4 polypeptides; or compounds which decrease, increase and/or otherwise enhance the production of IGS4 polypeptides, which comprises:



- (a) an IGS4 polypeptide, preferably that of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8;
- (b) a recombinant cell expressing an IGS4 polypeptide, preferably that of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8;
- 5 (c) a cell membrane expressing an IGS4 polypeptide; preferably that of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8; or
- (d) antibody to an IGS4 polypeptide, preferably that of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

10

### **Prophylactic and Therapeutic Methods**

This invention provides methods of treating abnormal conditions related to both an excess of and insufficient amounts of IGS4 activity.

15

If the activity of IGS4 is in excess, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as hereinabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit activation by blocking binding of ligands to the IGS4, or by inhibiting interaction with a RAMP polypeptide or a second signal, and thereby 20 alleviating the abnormal condition.

In another approach, soluble forms of IGS4 polypeptides still capable of binding the ligand in competition with endogenous IGS4 may be administered. Typical embodiments of such competitors comprise fragments of the IGS4 polypeptide.

25

In still another approach, expression of the gene encoding endogenous IGS4 can be inhibited using expression-blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or separately administered. See, for example, O'Connor, J Neurochem (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca 30 Raton, Florida USA (1988). Alternatively, oligonucleotides, which form triple helices with the gene, can be supplied. See, for example, Lee et al., Nucleic Acids Res (1979) 6:3073; Cooney et al., Science (1988) 241:456; Dervan et al, Science (1991) 251:1360. These oligomers can be administered per se or the relevant oligomers can be expressed in vivo. Synthetic antisense or triplex oligonucleotides may comprise modified bases or modified backbones. Examples of the latter include methylphosphonate, 35 phosphorothioate or peptide nucleic acid backbones. Such backbones are incorporated in the antisense or triplex oligonucleotide in order to provide protection from degradation by nucleases and are well known in the art. Antisense and triplex molecules synthesized with these or other modified backbones also form part of the present invention.



In addition, expression of the IGS1 polypeptide may be prevented by using ribozymes specific to the IGS1 mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, et al., Curr. Opin. Struct. Biol (1996) 6(4), 527-33.) Synthetic ribozymes can be designed to specifically cleave IGS1 mRNAs at selected positions thereby preventing translation of the IGS1 mRNAs into functional polypeptide. Ribozymes may be synthesized with a natural ribose phosphate backbone and natural bases, as normally found in RNA molecules. Alternatively the ribozymes may be synthesized with non-natural backbones to provide protection from ribonuclease degradation, for example, 2'-O-methyl RNA, and may contain modified bases.

For treating abnormal conditions related to an under-expression of IGS4 and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates IGS4, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of IGS4 by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo. For overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, Strachan T. and Read A.P., BIOS Scientific Publishers Ltd (1996).

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

#### **Formulation and Administration**

Peptides, such as the soluble form of IGS4 polypeptides, and agonists and antagonist peptides or small molecules, may be formulated in combination with a suitable pharmaceutical carrier. Such formulations comprise a therapeutically effective amount of the polypeptide or compound, and a pharmaceutically acceptable carrier or excipient. Formulation should suit the mode of administration, and is well within the skill of the art. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.



Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

Preferred forms of systemic administration of the pharmaceutical compositions include injection,

5 typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if properly formulated in enteric or encapsulated formulations, oral administration may also be possible.

10

The dosage range required depends on the choice of peptide or compound, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages are in the range of 0.1-100 µg/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and  
15 the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

20

Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide ex vivo, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

25

The following examples are only intended to further illustrate the invention in more detail, and therefore these examples are not deemed to restrict the scope of the invention in any way.



**EXAMPLE 1. THE CLONING OF cDNA ENCODING A NOVEL G PROTEIN-COUPLED RECEPTOR.**

**Example 1a. Homology PCR cloning of a genomic fragment encoding a novel G-protein coupled receptor (GPCR).**

5

A PCR based homology cloning strategy was used to isolate partial genomic DNA sequences encoding novel G-protein coupled receptors. Forward (F22) and reverse (R44 and R46) degenerate PCR primers were designed in conserved areas of the neuropeptide Y receptor gene family (Vita N. et al. [1993] *Febs Lett.* 317, 139-142; Vita N. et al. [1998] *Eur. J. Pharmacol.* 360, 265-272) within transmembrane domains 1 (TM1) and 3 (TM3) and at the boundary between TM3 and intracellular loop 2 (I2):

F22 (TM1):

5'-CTCATCTTCGCGGTGGGC(A or G)C(A,C,G or T)G(C or T)(A,C,G or T)GG-3' (SEQ ID NO: 13)

15

R44 (TM3/I2):

5'-GCCAGGCAGCGCTCCGCGCT(C or Inosine)A(A or G)(A,C,G or T)C(C or T)(A,C,G or T)GC(A,G or T)-3' (SEQ ID NO: 14)

20

R46 (TM3):

5'-GAA(A or G)TA(A or G)TAGCC(A or G)CG(A or G)CAGCC(A or T)-3' (SEQ ID NO: 15)

25

In order to suppress amplification of known members of the neuropeptide Y receptor family, the 3' ultimate nucleotide position of primer R44 was chosen in such a way that it was not complementary to the corresponding position of both NTR1 and NTR2 cDNA. The primary PCR reaction was carried out in a 60 $\mu$ l volume and contained 100ng human genomic DNA (Clontech), 6  $\mu$ l GeneAmp<sup>TM</sup> 10 x PCR buffer II (100mM Tris-HCl pH 8.3; 500 mM KCl, Perkin Elmer), 3.6  $\mu$ l 25 mM MgCl<sub>2</sub>, 0.36  $\mu$ l dNTPs (25mM of each dNTP), 1.5 units AmpliTaq-Gold<sup>TM</sup> polymerase (Perkin Elmer) and 30 pmoles of each of the degenerated forward (F22) and reverse primer (R44). Reaction tubes were heated at 95°C for 10 min and then subjected to 35 cycles of denaturation (95°C, 1 min), annealing (55°C, 2 min) and extension (72°C, 3min). Finally reaction tubes were heated for 10 min at 72°C.

30

For the semi-nested PCR reaction 1  $\mu$ l of a 1/50 dilution of the primary PCR reaction was used as a template using the degenerate forward and reverse primers F22 and R46 respectively. The semi-nested PCR reaction was carried out under the same conditions as the primary PCR reaction.

35

Semi-nested PCR reaction products were size fractionated on an agarose gel and stained with ethidium bromide. Although a fragment of  $\pm$  220 bp was expected, only a fragment of  $\pm$  120 bp was visible. This fragment was purified from gel using the Qiaex-II<sup>TM</sup> purification kit (Qiagen) and ligated into the pGEM-T plasmid according to the procedure recommended by the supplier (pGEM-T kit, Promega). The recombinant plasmids thus produced were used to transform competent *E. coli* SURE<sup>TM</sup> 2 bacteria (Stratagene). Transformed cells were plated on LB agar plates containing ampicillin (100  $\mu$ g/ml), IPTG (0.5 mM) and X-gal (50  $\mu$ g/ml). Plasmid DNA was purified from mini-cultures of individual colonies using



a Qiagen-tip 20 miniprep kit (Qiagen). DNA sequencing reactions were carried out on the purified plasmid DNA with the ABI Prism™ BigDye™ Terminator Cycle Sequencing Ready Reaction kit (PE-ABI), using insert-flanking primers.

5

**Table 7: Overview of oligo primers used.**

SEQ ID NO: 13	F22: 5'-CTCATCTTCGCGGTGGC(A or G)C(A,C,G or T)G(C or T)(A,C,G or T)GG-3'
SEQ ID NO: 14	R44: 5'-GCCAGGCAGCGCTCCGCGCT(C or Inosine)A(A or G)(A,C,G or T)C(C or T)(A,C,G or T)GC(A,G or T)-3'
SEQ ID NO: 15	R46: 5'-GAA(A or G)TA(A or G)TAGCC(A or G)CG(A or G)CAGCC(A or T)-3'
SEQ ID NO: 16	AP1: 5'-CCATCCTAATACGACTCACTATAAGGGC-3'
SEQ ID NO: 17	AP2: 5'-ACTCACTATAGGGCTCGAGCGGC-3'
SEQ ID NO: 18	IGS4R1: 5'GGATCCCAAATAAGAAAGGGTAGTTGC-3'
SEQ ID NO: 19	IGS4R2: 5'AAAGGGTAGTTGCGCCACATCTCATAGAC-3'
SEQ ID NO: 20	IGS4F5: 5'AGGTCTATGAGATGTGGCGCAACTACCCT-3'
SEQ ID NO: 21	IGS4F6: 5'ATGTGGCGCAACTACCCTTCTTATTGGG-3'
SEQ ID NO: 22	R74: 5'-CGGAAGTTGGCGGACACG(A or G)(A,C or G)(A or G)TT(A or G)TA-3'
SEQ ID NO: 23	IGS4F7: 5'-GCTCAGCTTGAAACAGAGCCTCGTACC-3'
SEQ ID NO: 24	IGS4F8: 5'-CCATGTGGATCTACAATTTCATCATCC-3'
SEQ ID NO: 25	IGS4F9: 5'-AAGACAAATCTCTTGAGGCAGATGAAGGG-3'
SEQ ID NO: 26	IGS4F10: 5'-GATGCTGTTGCTTGGCTTAGTGTTGC-3'
SEQ ID NO: 27	IGS4R5: 5'-GGATGATGAAATTGTAGATCCACATGGGC-3'
SEQ ID NO: 28	IGS4R6: 5'-TGTGGAGAAGTCTCTCAAAGTGTGG-3'
SEQ ID NO: 29	IGS4R7: 5'-TAGTAGGAGTGACAGCCTGACTCGGAACG-3'
SEQ ID NO: 30	IGS4R8: 5'-AACGTAGATGACTCAGGACGAACCATTCC-3'
SEQ ID NO: 31	IGS4F11: 5'-TCGTACCAGGGAGGCTCAGGC-3'

Sequencing reaction products were purified via EtOH/NaOAc precipitation and analyzed on an ABI 377  
10 automated sequencer.

Sequence analysis of the insert of clone HNT1552 showed that it potentially encoded part of a novel member of the GPCR family. We refer to this novel GPCR sequence as IGS4.

**Example 1b. Cloning of cDNA fragments containing the complete IGS4 coding sequence.**

15

The complete coding sequence of IGS4 cDNA was obtained via both RACE analysis (rapid amplification of cDNA ends) and RT-PCR amplification. 5'- and 3' RACE PCR reactions were performed on Marathon-Ready™ cDNA from human brain or testis (Clontech n° 7400-1 and 7414-1 respectively), using the adaptor primers 1 and 2 (AP1: SEQ ID NO: 16 ; AP2: SEQ ID NO: 17) provided with the



Marathon™ cDNA amplification kit (Clontech K1802-1) and IGS4 specific primers. PCR RACE reactions were performed according to the instructions of the Marathon-Ready™ cDNA user manual provided by Clontech. RACE products were separated on agarose gel, visualized with ethidium bromide and blotted onto Hybond N<sup>+</sup> membranes. Blots were prehybridized at 65°C for 2 h in modified Church buffer (0.5M phosphate, 7% SDS, 10 mM EDTA) and then hybridised overnight at 65°C in the same buffer containing 2 x 10<sup>6</sup> cpm / ml of a <sup>32</sup>P-labelled IGS4 cDNA probe. IGS4 cDNA probes were radiolabelled via random primed incorporation of [ $\alpha$ -<sup>32</sup>P]dCTP to a specific activity of > 10<sup>9</sup> cpm/ $\mu$ g using the Prime-It II kit™ (Stratagene) according to the instructions provided by the supplier. Hybridized blots were washed at high stringency (2 x 30 min at room temperature in 2 x SSC/ 0.1% SDS, followed by 2 washes of 40 min at 65°C in 0.1 x SSC, 0.1% SDS) and autoradiographed overnight. Hybridizing fragments were purified from a preparative gel, cloned into the pGEM-T vector and sequenced as described above.

An initial round of semi-nested 5' RACE analysis on human brain cDNA using the IGS4 specific primers IGS4R1 (SEQ ID NO: 18) and IGS4R2 (SEQ ID NO: 19)(designed on the DNA sequence of clone HNT1552) yielded clones HNT1886 and HNT1887 (Fig.1). These clones extended the IGS4 cDNA sequence upstream up to and beyond the putative start of translation codon. Likewise an initial round of 3' RACE analysis on human brain cDNA using IGS4 specific primers IGS4F5 (SEQ ID NO: 20) and IGS4F6 (SEQ ID NO: 21) yielded clones HNT1874-1878 and HNT1902-1903 (Fig.1). These clones extended the known IGS4 cDNA at the 3' end.

All sequences obtained at this point were assembled into a single contig which contained a long open reading frame, encoding part of a novel protein that was most similar to human orphan receptor FM-3 (Tan et al., Genomics 52, 223-229 [1998], GenBank accession n° AF044600 and AF044601). To investigate the RNA expression profile of IGS4, a Master Blot™ membrane (Clontech cat n° 7770-1) containing RNA from different human tissues was hybridized to the <sup>32</sup>P-labelled insert of clone HNT1903 under the conditions recommended by the supplier. The strongest hybridization was obtained with testis RNA whereas much weaker signals were obtained in prostate, stomach, spinal cord, hippocampus, medulla oblongata, thyroid gland, thymus, lung and trachea.

Since the contig sequence did not yet contain the complete IGS4 coding sequence we set up an RT-PCR homology cloning experiment on human total brain RNA using IGS4 specific primer IGS4F6 (SEQ ID NO: 21) and a degenerated primer (R74, SEQ ID NO: 22), which was designed in a conserved area (at the TM7/C-terminal intracellular part) of the GPCR subfamily composed of the neuropeptides receptors 1 and 2, the growth hormone secretagogue receptor (Howard A.D. et al.[1996] Science 273, 974-977) and the orphan GPCR FM-3 and GPR38 (McKee K.K. et al.[1997] Genomics 46, 426-434). RT-PCR reactions were carried out in a 50  $\mu$ l volume on 500 ng total RNA from human brain using the Titan™ One Tube RT-PCR System (Boehringer catalogue n° 1,888,382) according to the recommendations of the supplier. Briefly, RT-PCR conditions were as follows: reverse transcription for 45 min at 55°C; 2 min denaturation at 94°C, followed by a touch-down PCR reaction of 20 cycles (30 sec denaturation at 94°C, 30 sec annealing at 60°C [-0.25°C/cycle] and 2 min extension at 68°C) and an additional round of 30 PCR cycles (30 sec denaturation at 94°C, 30 sec annealing at 55°C and 3 min [+ 5 sec/cycle] extension at 68°C). This was concluded with an extra extension step of 7 min at 68°C.



Reaction products were analyzed via Southern blotting using the radiolabelled insert of clone HNT1903. A fragment of  $\pm$  690 bp that hybridized to the probe was purified from the gel (QiaexII™, Qiagen) and cloned into the pGEM-T vector yielding clones HNT2210-2212. Sequence analysis of these clones allowed to extend the existing IGS4 cDNA contig in the 3' direction.

5 Since the extended IGS4 cDNA contig still did not yet contain a translational stop codon, additional IGS4 specific 3' RACE primers were designed (IGS4F7-10, SEQ ID NO: 23-26)). Nested or semi-nested 3' RACE reactions were carried out on Marathon Ready™ cDNA from human testis (Clontech 7414-1). IGS4 specific bands (as assessed via Southern blot analysis using an IGS4 specific probe) were cloned into pGEM-T. This yielded clones HNT2289-90 (AP1/IGS4F5->AP2/IGS4F9),  
10 HNT2293-2295 (AP1/IGS4F6->AP2/IGS4F9), HNT2296-2297 (AP1/IGS4F7->AP2/IGS4F9), HNT2308-2310 (AP1/IGS4F8->AP2/IGS4F10) HNT2253 (AP1/IGS4F7->AP1/IGS4F5). An additional 5' RACE PCR reaction carried out on testis Marathon Ready™ cDNA yielded clones HNT2279-2281 (AP2/IGS4R6->AP2/IGS4R5). (note: AP1/IGS4F5->AP2/IGS4F9 e.g. indicates that clones were generated from an IGS4 specific fragment obtained after the primary RACE PCR reaction [using primer pair AP1/IGS4F5] was nested with primer pair AP2/IGS4F9).

15 Sequence analysis of these clones allowed to extend the existing IGS4 cDNA contig further in the 3' direction although the end of the IGS4 coding sequence was not yet been reached. A computer-assisted homology search (Blastn; Altschul S.F. et al., Nucleic Acids Res. (1997) 25:3389-3402) of the IGS4 contig DNA sequence against the expressed sequence tag (EST) database (dbest) showed the presence of an EST sequence (accession n° N45474) which overlapped with the 3' end of the IGS4 contig (near 100 % identity in the overlap area). EST N45474 further extended the IGS4 DNA contig at the 3' end into a translational stop codon and into the 3' untranslated region (3'-UTR). In addition another set of ESTs was identified which all covered the 3'-UTR of the IGS4 mRNA (Fig.2). Additional IGS4 specific primers (IGS4R7-8, SEQ ID NO: 29-30)) were designed within the 3'-UTR of these ESTs.  
20 Primary PCR reactions were carried out on Marathon Ready™ cDNA from human testis using various combinations of the IGS4F7 (SEQ ID NO: 23), IGS4F11 (SEQ ID NO: 31) and IGS4R7-8 (SEQ ID NO: 29-30) primers. PCR tubes were heated for 2 min at 95°C and then subjected to 35 cycles of denaturation (95°C, 30 sec), annealing (65°C, 30 sec) and extension (72°C, 1 min 30 sec). Finally the reactions tubes were heated at 72°C for 10 min. Nested PCR reactions were also carried out under the same conditions. DNA fragments of  $\pm$  1630 bp were purified from gel and cloned into the pGEM-T vector. The following clones were obtained: HNT2311, HNT2312 and HNT2317 (IGS4F7/IGS4R7->IGS4F11/IGS4R8); HNT2313, HNT2324, HNT2326 and HNT2328 (IGS4F11->IGS4R8); HNT2314, HNT2315 and HNT2322 (IGS4F11->R7). Clone HNT2363 was obtained from a purified 1630 bp PCR fragment, that was amplified from human testis Marathon Ready™ cDNA using the IGS4F11/R7 primer pair under the following slightly modified conditions. After an initial denaturation of 2 min at 94°C, PCR tubes were subjected to 15 cycles of denaturation [15 sec, 94°C], annealing [30 sec, 65°C] and extension [2 min, 72°C] followed by another 20 cycles of denaturation [15 sec, 94°C], annealing [30 sec, 65°C] and extension [2 min, 72°C; +10sec/cycle]. There was a final extension step of 7 min at 72°C. Sequence analysis of these clones allowed to assemble an IGS4 cDNA consensus sequence (Fig.1).



Close inspection of all clones showed that they actually were of 2 sequence types, which differed at 5 nucleotide positions. These variant sequences correspond to a polymorphism within the human population. We refer to these different cDNA types as IGS4ADNA (SEQ ID NO: 1 and SEQ ID NO: 3) and IGS4BDNA (SEQ ID NO: 5 and SEQ ID NO: 7). The consensus sequence contained a long open reading frame that contained two in-frame start codons (positions 55-57 (SEQ ID NO: 1 and SEQ ID NO: 5) and 64-66 (SEQ ID NO: 3 and SEQ ID NO: 7) in IGS4ADNA and IGS4BDNA), predicting a protein of either 415 (SEQ ID NO: 2 and SEQ ID NO: 6) or 412 (SEQ ID NO: 4 and SEQ ID NO: 8) amino acids, which showed good homology to GPCR proteins. Hydropathy analysis (Kyte J. et al.[1982] J. Mol. Biol. 157: 105-132; Klein P. et al.[1985] Biochim. Biophys. Acta 815:468-476) of the protein also indicated the presence of 7 transmembrane domains. Since the first ATG initiator codon is within a weak "Kozak" translation initiation context and the second one is in a strong Kozak context, it is likely that the IGS4A/B protein starts at the second methionine and is 412 amino acids long (Kozak M. [1999] Gene 234, 187-208). However some (or even exclusive) initiation at the first ATG cannot be excluded. Among the five polymorphic nucleotides, four (positions 947, 999, 1202 and 1216 in IGS4A/BDNA) resulted in a switch in the encoded amino acid residue, whereas the fifth (pos 1381 in IGS4A/BDNA) was within the 3'-UTR. The respective predicted protein sequences are referred to as IGS4APROT (SEQ ID NO: 2 and SEQ ID NO: 4) and IGS4BPROT (SEQ ID NO: 6 and SEQ ID NO: 8). (note 1: the sequence of IGS4APROT and IGS4BPROT in this document is represented as the longest possible (415 amino acids) sequence but it is understood that the actual protein might be 3 amino acids shorter at the amino-terminus; for this reason the first 3 amino acids of IGS4APROT and IGS4BPROT in Table 4 and 5 have been bracketed) (note 2: In this document IGS4 refers to the IGS4 sequence in general, irrespective of the particular allelic type). Homology searches of the IGS4 protein sequence against public domain protein databanks showed best homology to the human orphan GPCR FM-3 (accession no O43664, Tan C.P., et al. Genomics (1998) 52: 223-229; 46% identity in IGS4A amino acid residues 26-342).

Homology searches of DNA databanks with the IGS4 cDNA sequence yielded a number of entries which were also derived from the IGS4 gene locus (Fig.2 for overview):

- 10 EST sequence entries (accession nrs W61169, AI432384, W61131, AI023570, F01358, F03770, Z38158, R40869, R37725, H11333), 2 STS (sequence tagged sites) (accession nrs G20615 and G05725) and one genomic sequence (accession nr AQ078563) were discovered which were all derived from the 3'-UTR of IGS4 cDNA.
- EST accession n° N45474 encoded the 3' end of the IGS4 coding sequence and part of the 3' UTR (cfr supra).
- A 'working draft' high throughput genomic sequence (accession nr AC008571, version AC008571.1, deposited 3 AUG 1999), which consisted of 42 unordered contigs assembled in an arbitrary order was discovered in which we detected the entire IGS4 cDNA sequence in 4 separate areas. These areas most likely correspond to the different IGS4 exons as they were flanked by canonical splice donor and acceptor sequences. On the basis of this analysis the position of the different exons in the IGS4ADNA (or IGS4BDNA) sequence can be defined as follows: exon1 (1-780), exon 2 (781-865), exon 3 (866-991) and exon 4 (992-1658). The AC008571genomic sequence is of the IGS4A



allelic type.

- 6 overlapping EST entries (accession nrs H11359, R13890, R13353, F07531, F05108, F05107) were discovered of which the assembled DNA sequence overlapped at its 3' end with IGS4 exon2 and the beginning of exon 3. However the DNA sequence upstream of exon 2 was completely different from IGS4 exon1. Probably these six EST's are derived from transcripts which originated from an alternative promoter.
- Finally 2 genomic sequence entries (accession nrs AQ019411 and AQ015065) were discovered which encoded exon 2.

10 Among the many IGS4 cDNA clones that we isolated in the different experiments described above, we also discovered a number of clones that contained a 64 bp deletion (pos 866-929 in IGS4ADNA) (besides a number of clones derived from unspliced [or partially spliced] transcripts). So far we only discovered truncated transcripts of the polymorphic type A. We refer to this splice variant cDNA sequence as IGS4A-64DNA (SEQ ID NO: 9 and SEQ ID NO: 11). Since this deletion occurs exactly at  
15 the exon 2/exon 3 boundary and since the last 2 nucleotides of the deleted fragment are "AG", it is likely that this deletion represents an alternative splicing event in which the "AG" within exon 3 served as a splice acceptor. The IGS4A reading frame encoded by the splice variant is frameshifted beyond the deletion point. The encoded (truncated) protein of 296 amino acids is referred to as IGS4A-64PROT (SEQ ID NO: 10 and SEQ ID NO: 12). Hydropathy analysis of the IGS4A-64PROT sequence shows that  
20 this protein only contains 5 transmembrane domains (corresponding to TM domains 1-5 of IGS4APROT). This truncated receptor might have physiological relevance.

The bacterial strain harboring plasmid HNT2322 (containing the IGS4ADNA insert) was recloned after replating on LB agar plates containing 100 µg ampicillin/ml and deposited both in the  
25 Innogenetics N.V. strain list (ICCG4320) and at the "Centraalbureau voor Schimmelculturen (CBS)" in Baarn, The Netherlands (accession n° CBS102221). Plasmid DNA was prepared from the recloned isolate and the insert was resequenced and found to be identical to the IGS4ADNA sequence.

The bacterial strain harboring plasmid HNT2363 (containing the IGS4BDNA insert) was recloned after replating on LB agar plates containing 100 µg ampicillin/ml and deposited both in the  
30 Innogenetics N.V. strain list (ICCG4340) and at the "Centraalbureau voor Schimmelculturen (CBS)" in Baarn, The Netherlands (accession n° CBS102222). Plasmid DNA was prepared from the recloned isolate and the insert was resequenced and found to be identical to the IGS4BDNA sequence.



**EXAMPLE 2. SPECIFIC CHANGES IN INTRACELLULAR CALCIUM CONCENTRATIONS INDUCED  
IN CHOG 16-IGS4 CELLS BY NEUROMEDIN U.**

**Example 2a. Experimental Procedures: Method and Materials.**

5

**A. Method and Materials for IGS-4 transfected CHOG 16-cells.**

The following materials were used in the experiments: Vector containing IGS4-DNA sequence (IGS4-pcDNA3.1); SuperFect Transfection Reagent (Qiagen); Nut-Mix F12 (Gibco) with 10% FCS, 0.028mg/ml Gentamycin (Gibco); 0.22mg/ml Hygromycin (Gibco).

10 Materials used for clone selection: Nut-Mix F12 with 10% FCS; 0.028mg/ml Gentamycin; 0.22mg/ml Hygromycin and 0.55mg/ml Geneticin (Gibco).

15 The following method was applied: Transfection with SuperFect Transfection Reagent was carried out as described by the manufacturer (Qiagen). Cells were plated in 24-well plates to 50% confluence. Per well 0.6 $\mu$ g/ $\mu$ l plasmid-DNA with 1 $\mu$ l SuperFect Transfection Reagent was added. After 24 hours the medium was changed and transfected cell clones were selected by Geneticin-containing selection-medium. IGS4 expressing cell clones were characterized by RT-PCR and Northern Blot.

**B. Method and Materials for FLIPR-Assay.**

20 Cell Preparation:

For cell preparation the following materials were employed: plates: clear, flat-bottom, black well 96-well plates (Costar); Media: growth medium: Nut-Mix F-12 (HAM) with Glutamax (Gibco) supplemented with 10% fetal calf serum (Gibco); Incubator: 5% CO<sub>2</sub>, 37°C (Nuaire).

25 The method was performed as follows: Cells were seeded 24 hours or 48 hours prior to the experiment into black wall microplates. The cell density was 0.8x10<sup>4</sup> cells/well for 48 hour incubation and 2.2x10<sup>4</sup> cells/well for 24 hour incubation. All steps were done under sterile conditions.

Dye loading:

30 In order to observe changes in intracellular calcium levels, cells must be 'loaded' with a calcium-sensitive fluorescent dye. This dye, called FLUO-4 (Molecular Probes) is excited at 488nm, and emits light in the 500-560nm range, only if a complex with calcium is formed. The dye was used at 4 $\mu$ M final concentration. Pluronic acid was added to increase dye solubility and dye uptake into the cells. Probenicid, an anion exchange protein inhibitor, was added to the dye medium to increase dye retention

35 in the cells.

The following materials were used:

- 2mM dye stock: 1mg Fluo-4 (Molecular Probes) solubilized in 443 $\mu$ l low-water DMSO (Sigma). Aliquots stored at -20.



- 20% pluronic acid solution: 400mg pluronic acid (Sigma) solubilized in 2ml low-water DMSO (Sigma) at 37°C. Stored at room temperature.
- Dye/pluronic acid mixture: Immediately before use, equal volumes of the dye stock and 20% pluronic acid were mixed. The dye and pluronic acid had a final concentration of 1mM and 10%, respectively.
- Probenicid, 250mM stock solution: 710mg probenicid (Sigma) solubilized in 5ml 1N NaOH and mixed with 5ml Hank's BSS without phenol red (Gibco) supplemented with 20mM HEPES.
- Loading-Buffer: 10.5ml Hank's BSS without phenol red (Gibco) supplemented with 20mM HEPES, 105µl probenicid, 210µl 1M HEPES.
- Wash-Buffer: Hank's BSS without phenol red (Gibco) supplemented with 20mM HEPES (Gibco) and 2.5mM probenicid.

The method was worked as follows: The 2mM stock of dye was mixed with an equal volume of 20% (w/v) pluronic acid immediately before adding to the loading-Buffer. The growth-medium was aspirated out of the well without disturbing the confluent cell layer. 100µl loading medium was dispensed into each well using a Multidrop (Labsystems). Cell were incubated in a 5% CO<sub>2</sub>, 37°C incubator for 30 minutes. In order to calculate the background fluorescence, some wells were not dye loaded. The background fluorescence in these wells results from autofluorescence of the cells. After dye loading, cell were washed three times with Wash-Buffer (automated Denley cell washer) to reduce the basal fluorescence to 20.000-25.000 counts above background. 100 µl buffer was added and cell were incubated at 37°C till start of the experiment.

#### C. Preparation of compound plates.

The peptides were prepared at 3µM (3x the final concentration) for initial screening. For concentration response curves peptide-solutions were prepared in concentration ranges from 30µM to 100nM. All peptides were diluted in buffer containing 0.1% BSA (Sigma).

The following materials were used: Peptides: porcine Neuromedin U25, rat Neuromedin U-23, porcine Neuromedin U-8 (Bachem); Dilutionbuffer: Hank's BSS without phenol red (Gibco) supplemented with 20mM HEPES (Gibco) and 0.1% BSA (Sigma); plates: clear, flat-bottom, 96-well plates (Costar).

30

#### D. Assay.

The FLIPR setup parameters were set to 0.4 sec exposure length, filter 1, 50µl fluid addition, pipettor height at 125µl, Dispense Speed 40µl/sec without mixing.

35      **Example 2b. Results.**

To identify the endogenous ligand for the orphan G protein coupled receptor (GPCR) IGS4, IGS4 (both forms IGS4A and IGS4B) was stably transfected in Chinese Hamster Ovary (CHO) cells. Since the G protein coupling mechanism of IGS4 was unknown, a specific CHO-cell strain was used. These CHO-



cells stably express the G-protein G 16 (CHOG 16, Molecular Devices), which is known as "universal adapter" for GPCRs (Milligan G., Marshall F. and Rees S. (1996), Ga16 as a universal G protein adapter: implications for agonist screening strategies. *TIPS* 17: 235-237).

The resulting CHOG 16-IGS4 cells were functionally screened on a Fluorometric Imaging Plate Reader

5 (FLIPR) to measure mobilisation of intracellular calcium in response to putative peptide ligands.

At the concentration of 10nM neuromedin U-23 induced a large, transient and robust calcium-response.

In contrast, CHOG 16 cells and CHOG 16 cells expressing another, unrelated orphan GPCR, did not respond to neuromedin U-23. The results of these experiments with IGS4B are shown in Fig. 4.

10 Furthermore, the concentration dependence of IGS4 activation by porcine and rat neuromedin U isoforms were investigated (for both forms IGS4A and IGS4B). In the range of 10<sup>-6</sup>-10<sup>-12</sup> M porcine neuromedin U-25, rat neuromedin U-23, porcine neuromedin U-8 induced specific IGS4-mediated calcium mobilisation in the FLIPR assay. All three Neuromedin U isoforms tested caused the same maximal activation of IGS4B with LogE.C<sub>50</sub> values of -10.09 ± 0.08 (neuromedin U-8, n=4; 80 pM),

15 -10.61± 0.08 (neuromedin U-23, n=10; 50 pm) and -9.14 ± 0.09 (neuromedin U-25, n=3; 1.2 nM). Thus, all three peptides cause potent activation of in particular IGS4B, suggesting that neuromedin U is the natural agonist for this receptor. The results of these experiments with IGS4B are shown in Fig. 3a (neuromedin U-8), Fig. 3b (neuromedin U-23) and Fig. 3c (neuromedin U-25).

20 For the IGS4A receptor somewhat lower affinities were found, but still showing that the neuromedin U peptides are good ligands for IGS4 receptors in general. The log EC<sub>50</sub> values found for IGS4A were as follows; for neuromedin U-8: log EC<sub>50</sub> = -9.3 ± 0.09 (n=1; 485 pM); for neuromedin U-23: log EC<sub>50</sub> = -7.27 ± 0.16 (n=6; 53 nM); and for neuromedin U-25: log EC<sub>50</sub> = -6.18 ± 0.14 (n=3; 658 nM).

25 The calcium mobilisation response seen following activation of IGS4 by neuromedin U suggests that this receptor is coupled to G proteins of the Gq/11 subfamily. In addition, basal levels of intracellular cAMP were not modulated by porcine neuromedin U-8 (1 and 10μM) in CHOG 16-IGS4 cells, suggesting that this receptor does not couple to G proteins of the Gs subfamilies (data not shown).

30

### EXAMPLE 3. IGS4 HYBRIDIZATION ON HUMAN MULTIPLE TISSUE EXPRESSION ARRAY (MTE<sup>TM</sup>)

Human IGS4A DNA (± 730 bp BamHI / HindIII insert from pGEMT-hIGS4A [ICCG #4320] ) was radiolabelled via random primed incorporation of [<sup>32</sup>P]-dCTP to a specific activity of > 10<sup>9</sup> cpm/μg using the Prime-It II kit<sup>TM</sup> (Stratagene). The labeled probe was purified from free label via Sephadex G-50 chromatography, denatured for 5 min. at 95°C and added to the ExpressHyb hybridization solution at a final concentration of 1-1.5 x 10<sup>6</sup> cpm/ml. The human Multiple Tissue Expression (MTE<sup>TM</sup>) Array (Clontech # 7775-1) was prehybridized and hybridized in ExpressHyb solution at 65°C for 30 min and overnight respectively according to the recommendations of the supplier.



The hybridized MTE™ array was washed 5 times for 20 min in 2 x SSC, 1% SDS at 65°C and then 2 times for 20 min at 55°C in 0.1 x SSC, 0.5% SDS. After the washes the array was autoradiographed via phosphorimaging (Cyclone Storage Phosphor System, Packard) (Fig.5). Hybridization data of the 5 MTE™ array were analyzed quantitatively using the OptiQuant Image Analysis Software (Packard). Signal intensity of different spot positions containing RNA was corrected for the average background signal obtained from empty positions. The signal intensity obtained from the spot containing E. coli DNA was considered to represent a sample exhibiting no IGS4 expression. Samples with signal intensities below that of E. coli DNA were considered to be negative.

10

Hybridization signals for different tissues on the RNA array have been recalculated by subtracting each value with the hybridization signal observed for E. coli DNA (which is considered as the background signal). All tissues showing a lower hybridization signal are considered to be below background and to 15 be IGS4 negative. Expression levels relative to that found in testis (100%) have been plotted and are provided in Fig.7.

#### EXAMPLE 4. TISSUE DISTRIBUTION OF IGS4 BY NORTHERN BLOT ANALYSIS

20

Human IGS4A DNA ( $\pm$  730 bp BamHI / HindIII insert from pGEMT-hIGS4A [ICCG #4320] ) was radiolabelled via random primed incorporation of [ $\text{s}^3\text{P}$ ]-dCTP to a specific activity of  $> 10^9$  cpm/ $\mu\text{g}$  using the Prime-It II kit™ (Stratagene). The labeled probe was purified from free label via Sephadex G-50 chromatography, denatured for 5 min. at 95°C and added to the ExpressHyb hybridization solution at 25 a final concentration of  $1-1.5 \times 10^6$  cpm/ml. The human Northern blots ( Clontech #7760-1, #7759-1, #7767-1, #7755-1 and #7769-1) were prehybridized and hybridized in ExpressHyb solution at 65°C for 30 min and overnight respectively according to the recommendations of the supplier.

After hybridization Northern blots were washed 4 times 10 min at room temperature in 2 x SSC, 0.05 % 30 SDS and then 2 times 40 min at 50°C in 0.1 x SSC, 0.1% SDS. After the washes the Northern blots were autoradiographed using phosphor storage plates (Cyclone Storage Phosphor System, Packard) and X-ray films. Results of Northern blots are shown in Fig.6.

The results of the Northern blot analysis appear to be largely consistent with those from the array 35 hybridization (Example 3). The strongest signal (2.4 kb transcript) by far is found in testis. A weak 2.4 kb band was found in thymus, spinal cord, medulla, thyroid, thalamus, substantia nigra and a very weak band in corpus callosum, caudate nucleus and stomach. For some tissues no 2.4 kb band could be seen on Northern whereas a strong to moderate hybridization signal was observed on the MTE array (e.g. whole brain, cerebral cortex, lung, temporal and frontal lobe, amygdala, cerebellum, kidney and 40 hippocampus).



**EXAMPLE 5. QUANTITATIVE RT-PCR ANALYSIS.**

IGS4 expression levels in different human tissues were also determined via real-time quantitative RT-  
5 PCR (Q-PCR) using the LightCycler™ instrument (Roche Diagnostics) and IGS4 specific TaqMan™  
probes.

**Example 5a. Experimental procedures.****10 A. cDNA synthesis.**

Prior to reverse transcription 3 µg total RNA from the human total RNA panels I to V (Clontech # K4000-  
1 to K4004-1) was treated with 3U DNase I (Life Technologies # 18068-015) in a 30 µl reaction volume  
(20 mM Tris pH 8.3, 50 mM KCl, 2 mM KCl) for 15 min at room temperature to destroy possibly  
contaminating genomic DNA. The reaction was stopped by adding 3 µl 25 mM EDTA and heating for 10  
15 min at 65°C. 2,6 µg of the DNase treated RNA was annealed with 1,3 µg oligo(dT) (Life Technologies #  
18418-012) and subjected to reverse transcription using the Omniscript reverse transcriptase (Qiagen  
cat n° 205111) for 1 h at 37°C in a 52 µl reaction volume according to the protocol recommended by the  
supplier of the enzyme. The Omniscript reverse transcriptase was inactivated by heating at 93°C for 5  
min.

20

**B. Q-PCR.**

Quantitative PCR reactions were carried out in a 20 µl reaction mixture, containing 1X TaqMan™  
Universal PCR Mastermix (PE Applied Biosystems cat #4304437), 0.12 mg BSA/ml, 900 nM of IGS4  
specific forward and reverse primers (IP14,963 and IP14,964), 250 nM of the IGS4 specific TaqMan™  
25 probe (IP14,962) and either 1.6 µl (IGS4) or 0.16 µl (GAPDH: glyceraldehyde-3 phosphate  
dehydrogenase) of the cDNA synthesis reaction as template. To set up the IGS4 standard curve a  
dilution series (10<sup>7</sup> -10<sup>1</sup>copies/ reaction) of IGS4 plasmid ICCG 4320 was used whereas for the GAPDH  
standard curve a dilution series of the human brain cDNA synthesis reaction (0.16 µl, 0.016 and 0.0016  
µl) was used as template. The 1X TaqMan™ Universal PCR Mastermix contained AmpliTaq Gold™  
30 DNA polymerase, AmpErase™ UNG (uracil-N-glycosylase), dNTPs with dUTP, passive reference and  
optimized buffer components. IGS4 specific primers and TaqMan probe were designed using the Primer  
Express™ software (PE Applied Biosystems). Quantitative PCR reactions for human GAPDH were  
carried out under identical conditions as described for IGS4 except that GAPDH specific primers and  
TaqMan™ probe were used from the TaqMan™ GAPDH control reagents kit (PE Applied Biosystems  
35 cat n° 402869; sequence information not available from PE Applied Biosystems).

PCR reactions were carried out in glass capillary cuvettes in the LightCycler™ instrument. After  
an initial incubation at 50°C for 2 min to allow the AmpErase™ UNG reaction to proceed and activation  
of the AmpliTaq Gold DNA polymerase (95°C for 10 min), reaction mixtures were subjected to 40 cycles  
of denaturation (15 sec at 95°C) and annealing/extension (1 min at either 60 °C [GAPDH] or at 68°C



[IGS4]). Quantification of experimental samples was carried out using the LightCycler Software version 3.0. A good linear relationship was obtained between the amount of IGS4 plasmid and the release of reporter dye within the range of 10-10<sup>7</sup> IGS4 plasmid copies. We also obtained a linear standard curve with the GAPDH TaqMan™ probe using the serially diluted brain cDNA. Relative GAPDH expression levels were in the range of 0.4 to 10.2 % of that observed in skeletal muscle, which of all tissues tested had the highest GAPDH expression level. Relative IGS4 expression levels were expressed as a proportion of the level detected in spinal cord, which had the highest IGS4 expression of all tissues tested (Fig.8). We also plotted relative IGS4 expression levels after normalization for expression of the GAPDH house keeping gene (Fig.8).

10

**Example 5b. Results.**

Q-PCR using an IGS4 specific TaqMan probe showed that highest expression levels (without normalization for GAPDH) were found in spinal cord. IGS4 expression levels in spinal cord amounted to 11,467 copies mRNA / ng pA RNA (assuming 100 % efficiency of the cDNA synthesis reaction and assuming that pA RNA constitutes 2% of total RNA). High IGS4 expression levels were also found in brain (41 % of spinal cord levels), skeletal muscle (37%), cerebellum (31%), testis (19%) and in lung (12%) and heart (11%). Lower levels were found in fetal brain (5%), trachea (4%), prostate (2%) and thyroid (1.4%). After normalization for GAPDH expression, the relative IGS4 expression pattern remained largely unchanged with the exception of skeletal muscle, where the relative expression level dropped to 2% of that in spinal cord. As it is not clear whether normalization for GAPDH is a valid procedure (GAPDH expression levels can be expected to vary more or less in different cell/ tissue types) we prefer to focus on the non-normalized relative expression levels.

These Q-PCR data seem to be in line with expression data from RNA array (Example 3) and 25 Northern blot (Example 4) hybridization experiments in the sense that testis, spinal cord and brain appear to be among the most prominent expression sites. However Q-PCR analysis additionally shows important expression in a number of other tissues, such as skeletal muscle, cerebellum, lung and heart.

The ligand neuromedin U has been proposed to be a neuropeptide or neuromodulator, without the 30 knowledge of the specific receptor (Domin J., Ghatei M. A., Chohan P. and Bloom S. R. (1987), Peptides 8: 779-784). Our investigation shows, that IGS4 is a novel member of the neuromedin U-receptor family being expressed in CNS and PNS regions, the gastrointestinal, immunological, genitourinary and cardiovascular system, skeletal muscle, thyroid, and lung.

35

**Table 8: Overview of the PCR oligonucleotide primers and TaqMan probe used in the IGS4 Q-PCR reactions.**

SEQ ID NO: 32	IP 14,963	5'-CCTCTTCAGCCTGGCGGTCTCTG-3'
---------------	-----------	-------------------------------



SEQ ID NO: 33	IP 14,964	5'- GGAGGCGAAGCACACGGTCTCA-3'
SEQ ID NO: 34	IP 14,962	5'(FAM)-AGATGTGGCGCAACTACCCTTCTGTTGGGCC- (TAMRA)3'

All publications, including but not limited to patents and patent applications, cited in this specification are  
herein incorporated by reference as if each individual publication were specifically and individually  
5 indicated to be incorporated by reference herein as though fully set forth.



**The figures show:**

Fig.1 Schematic representation of the relative positions of the different cDNA clones that were isolated to generate the consensus IGS4 cDNA sequence. 5' and 3' RACE primers that were used are also indicated (IGS4R# and IGS4F# respectively) as well as the position of EST accession n° N45474. Primer IGS4R6 was located within intron 1. Some clones (e.g. HNT2311, HNT2312 and HNT2253) were only partially sequenced (only the part that was sequenced is indicated). CONSENSUS A and CONSENSUS B denote the consensus sequence of IGS4 allelic types A and B respectively. The nucleotide that was identified at each of the 4 polymorphic positions is indicated (shaded boxes) for each clone. "S" indicates a sequence ambiguity in clones HNT2211 and HNT2212 and means either "C" or "T". The coding area of IGS4A and IGS4B consensus sequences is indicated with \*\*\*. As there were some remaining sequence ambiguities in the 5' end of the consensus sequence, the IGS4ADNA and IGS4BDNA sequences have only been taken from position 86 until the end

Fig.2 Schematic representation of the relative positions of different DNA database entries compared to the IGS4 cDNA sequence. The IGS4 cDNA sequence is indicated with the boxes (the position of the IGS4 coding sequences is indicated with the filled boxes). The relative position of IGS4 exons 1-4 is indicated above the IGS4 cDNA sequence ("=="). The parts of the genomic sequence AC008571 that encode exons 1->4 are indicated with AC008571a->d respectively. The position of these fragments within the AC008571 sequence are: AC008571a (13129-13908 of the reverse complement of AC008571), AC008571b (51676-51760 of AC008571), AC008571c (79978-80103 of the reverse complement of AC008571) and AC008571d (83060-83728 of the reverse complement of AC008571). G05725 and G20615 are STS (sequence tagged sequence) entries whereas F05107, F05108, F07531, R13353, R13890, H11359, N45474, W61169, AI432384, W61131, AI023570, F01358, F03770, Z38158, R40869, R37725, H11333 are EST entries. The parts of genomic clones AQ019411 and AQ015065 that contain IGS4 exon 2 are indicated with ":". The 5' part of EST sequences F05107, F05108, F07531, R13353, R13890 and H11359 which is totally different from the IGS4 cDNA sequence is indicated with \*\*. AQ078563 is a genomic clone.

Fig.3 : IGS4 receptor activation by different Neuromedin U isoforms. CHOG 16-IGS4B cells were cultured in 96-well plates overnight and loaded with Fluo-4AM. The receptor mediated Ca<sup>2+</sup> changes were measured with FLIPR (Molecular Devices). Maxima of the fluorescence change detected by the CCD camera were normalised to 1 and are depicted as counts.  
Fig. 3a: results for neuromedin U-8;  
Fig. 3b: results for neuromedin U-23;  
Fig. 3c: results for neuromedin U-25.



Fig.4 Neuromedin U-23 induced intracellular  $\text{Ca}^{2+}$  mobilisation in CHOG 16-cells expressing IGS4B. Application of 10nM Neuromedin U-23 to the cell lines CHOG 16-IGS4, CHOG 16 and CHOG 16 transfected with an other orphan GPCR. Cells were cultured in 96-well plates overnight and loaded with Fluo-4AM. Receptor mediated intracellular  $\text{Ca}^{2+}$  changes were measured with FLIPR (Molecular Devices), depicted in counts detected by the CCD camera.

5 Fig. 5 Human multiple tissue expression array using a human IGS4 probe.

10 Fig. 6 Northern blot analysis using an IGS4 probe.

Fig. 7 IGS4 expression analysis (MTE blot).

15 Fig. 8 Relative expression levels of IGS4 mRNA as compared to the expression observed in spinal cord. Both non-normalized and GAPDH-normalized expression levels are shown.



Original (for SUBMISSION) - printed on 25.09.2000 12:53:10 PM

0-1	Form - PCT/RO/134 (EASY) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared using	PCT-EASY Version 2.90 (updated 15.12.1999)
0-2	International Application No.	<b>PCT/EP 00 / 09584</b>
0-3	Applicant's or agent's file reference	SPW99.06
1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:  1-1 page 1-2 line	44 25>
1-3	Identification of Deposit 1-3-1 Name of depositary institution 1-3-2 Address of depositary institution	Centraalbureau voor Schimmelcultures Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, Netherlands
1-3-3	Date of deposit	24 September 1999 (24.09.1999)
1-3-4	Accession Number	CBS 102221
1-4	Additional Indications	none
1-5	Designated States for Which Indications are Made	all designated States
1-6	Separate Furnishing of Indications  These indications will be submitted to the International Bureau later	none
2	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:  2-1 page 2-2 line	44 30>
2-3	Identification of Deposit 2-3-1 Name of depositary institution 2-3-2 Address of depositary institution	Centraalbureau voor Schimmelcultures Oosterstraat 1, Postbus 273, NL-3740 AG Baarn, Netherlands
2-3-3	Date of deposit	24 September 1999 (24.09.1999)
2-3-4	Accession Number	CBS 102222
2-4	Additional Indications	none
2-5	Designated States for Which Indications are Made	all designated States
2-6	Separate Furnishing of Indications  These indications will be submitted to the International Bureau later	none

## FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the international application: (yes or no)	27.09.2000
-----	---	------------



Original (for SUBMISSION) - printed on 25.09.2000 12:53:10 PM

0-4-1	Authorized officer	
-------	--------------------	---

**FOR INTERNATIONAL BUREAU USE ONLY**

0-5	This form was received by the international Bureau on:	
0-5-1	Authorized officer	



**Claims**

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
  - a) a nucleotide sequence encoding the IGS4 polypeptide according to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8.
  - b) a nucleotide sequence encoding the polypeptide encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands, in particular a nucleotide sequence corresponding to the SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7.
  - c) a nucleotide sequence having at least 80 % (preferably at least 90%) sequence identity over its entire length to the nucleotide sequence of (a) or (b);
  - d) a nucleotide sequence which is complimentary to the nucleotide sequence of (a) or (b) or (c).
2. The polynucleotide of claim 1 wherein said polynucleotide comprises the nucleotide sequence contained in SEQ ID NO: 1 encoding the IGS4 polypeptide of SEQ ID NO: 2 or the nucleotide sequence contained in SEQ ID NO: 3 encoding the IGS4 polypeptide of SEQ ID NO: 4 or the nucleotide sequence contained in SEQ ID NO: 5 encoding the IGS4 polypeptide of SEQ ID NO: 6 or the nucleotide sequence contained in SEQ ID NO: 7 encoding the IGS4 polypeptide of SEQ ID NO: 8.
3. The polynucleotide of claim 1 wherein said polynucleotide comprises a nucleotide sequence that is at least 80% identical to that of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 or to the sequence of the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands over its entire length.
4. The polynucleotide of claim 3 which is the polynucleotide of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 or the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands.
5. The polynucleotide of claim 1-4 which is DNA or RNA.



6. An isolated nucleotide sequence encoding an IGS4 neuromedin receptor protein, preferably a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25.  
5
  7. An isolated nucleotide sequence of claim 6 encoding an IGS4 neuromedin receptor protein, said protein exhibiting expression in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea.  
10
  8. An isolated nucleotide sequence encoding an IGS4 neuromedin receptor protein, preferably a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, said protein exhibiting expression in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea, and said nucleotide sequence being selected  
15
  9. A DNA or RNA molecule comprising an expression system, wherein said expression system is capable of producing an IGS4 polypeptide comprising an amino acid sequence, which has at least 80% identity with the polypeptide of SEQ ID NO: 2, SEQ  
20
  - 25
  - 30
  - 35
10. An isolated DNA or RNA molecule comprising an expression system, wherein said expression system is capable of producing an IGS4 polypeptide comprising an amino acid sequence which is a neuromedin receptor protein, preferably a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, and exhibiting expression in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus



accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea.

11. A host cell comprising the expression system of claim 9 or 10.  
5
12. A host cell according to claim 11 which is a yeast cell.
13. A host cell according to claim 11 which is an animal cell.
- 10 14. IGS4 receptor membrane preparation derived from a cell according to claim 11-13.
- 15 15. A process for producing an IGS4 polypeptide comprising culturing a host of claim 11-13 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.  
15
16. A process for producing a cell which produces an IGS4 polypeptide comprising transforming or transfecting a host cell with the expression system of claim 9 or 10 such that the host cell, under appropriate culture conditions, produces an IGS4 polypeptide.
- 20 17. An IGS4 polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO: 2, SEQ NO: 4, SEQ NO: 6 or SEQ NO: 8 or to the polypeptide encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands over its entire length.  
25
18. The polypeptide of claim 17 which comprises the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands.  
30
19. An isolated IGS4 polypeptide comprising an amino acid sequence of a neuromedin receptor protein, preferably of a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25.  
35
20. An isolated IGS4 polypeptide of claim 19 comprising an amino acid sequence of a neuromedin receptor protein, said protein exhibiting expression in brain, skeletal muscle,



cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea.

- 5      21. An isolated IGS4 polypeptide comprising an amino acid sequence of a neuromedin receptor protein, preferably a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, said protein exhibiting expression in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea, and said amino acid sequence being selected from the group of amino acid sequence as defined in the claims 17-18.
- 15     22. An antibody immunospecific for the IGS4 polypeptide of claim 17-21.
23. A method for the treatment of a subject in need of enhanced activity or expression of IGS4 polypeptide of claim 17-21 comprising:
- 20        (a) administering to the subject a therapeutically effective amount of an agonist to said receptor; and/or
- 25        (b) providing to the subject an isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the IGS4 polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the polypeptide encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands over its entire length; or a nucleotide sequence complementary to one of said nucleotide sequences in a form so as to effect production of said receptor activity in vivo.
- 30        (c) providing to the subject an isolated polynucleotide comprising a nucleotide sequence that encodes an IGS4 neuromedin receptor protein, preferably a mammalian IGS4 neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25.
- 35     24. A method for the treatment of a subject having need to inhibit activity or expression of IGS4 polypeptide of claim 17-21 comprising:



- (a) administering to the subject a therapeutically effective amount of an antagonist to said receptor; and/or
  - (b) administering to the subject a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said receptor; and/or
  - 5 (c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said receptor for its ligand.
25. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of the IGS4 polypeptide of claim 17-21 in a subject comprising:
- 10 (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said IGS4 polypeptide in the genome of said subject; and/or
- (b) analyzing for the presence or amount of the IGS4 polypeptide expression in a sample derived from said subject.
- 15 26. A method for identifying agonists to the IGS4 polypeptide of claim 17-21 comprising:  
(a) contacting a cell which produces a IGS4 polypeptide with a test compound; and  
(b) determining whether the test compound effects a signal generated by activation of the IGS4 polypeptide.
- 20 27. An agonist identified by the method of claim 26.
28. A method for identifying agonists to the IGS4 neuromedin receptor protein, preferably to the mammalian IGS4 neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or 25 for neuromedin U-25, comprising:  
(a) contacting a cell which produces a IGS4 neuromedin receptor protein with a test compound; and  
(b) determining whether the test compound effects a signal generated by activation of the IGS4 neuromedin receptor protein.
- 30 29. A method for identifying agonists to the IGS4 neuromedin receptor protein according to claim 28, wherein said agonists are effective with regard to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, 35 immunological diseases and disorders of the genitourinary system.



30. An agonist identified by the method of claim 28 or 29, preferably an agonist being effective with regard to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system.  
5
31. A method for identifying antagonists to the IGS4 polypeptide of claim 17-21 comprising:
  - (a) contacting a cell which produces a IGS4 polypeptide with an agonist; and
  - 10 (b) determining whether the signal generated by said agonist is diminished in the presence of a candidate compound.
32. An antagonist identified by the method of claim 31.
- 15 33. A method for identifying antagonists to the IGS4 neuromedin receptor protein, preferably to the mammalian IGS4 neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, comprising:
  - (a) contacting a cell which produces a IGS4 neuromedin receptor protein with an agonist; and
  - 20 (b) determining whether the signal generated by said agonist is diminished in the presence of a candidate compound.
34. A method for identifying antagonists to the IGS4 neuromedin receptor protein according to claim 33, wherein said antagonists are effective with regard to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system.  
25
- 30 35. An antagonist identified by the method of claim 33 or 34, preferably an antagonist being effective with regard to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system.  
35



36. A recombinant host cell produced by a method of claim 16 or a membrane thereof expressing an IGS4 polypeptide.

37. A method of creating a genetically modified non-human animal comprising the steps of:

5 (a) ligating the coding portion of a nucleic acid molecule, consisting essentially of a nucleic acid sequence encoding a protein having the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands or a  
10 biologically active portion of one of said sequences, to a regulatory sequence which is capable of driving high level gene expression or expression in a cell type in which the gene is not normally expressed in said animal; or

15 (b) isolation and engineering the coding portion of a nucleic acid molecule, consisting essentially of a nucleic acid sequence encoding a protein having the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands or a biologically active portion of one of said sequences, and reintroducing said sequence in the genome of said animal in such a way that the endogenous gene  
20 alleles, encoding a protein having the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands or a biologically active portion of one of said sequences, are fully or partially inactivated.

25

38. A method of determining whether a substance is a potential ligand of IGS4 receptor comprising:

30 (a) contacting cells expressing the receptor of one of the claims 17-21 or one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8, or contacting a receptor membrane preparation comprising one of said receptors of one of the claims 17-21 or one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8 with labeled neuromedin U in the presence and in the absence of the substance; and


(b) measuring the binding of neuromedin U to IGS4.



39. A polypeptide according to any of the claims 17-21, further being characterized in that said polypeptide binds neuromedin U, preferably neuromedin U-8, neuromedin U-23 and/or neuromedin U-25, showing at least an affinity of about  $\log EC_{50} = -6$ .
- 5    40. A polypeptide according to any of the claims 17-21, further being characterized in that said polypeptide binds neuromedin U, preferably neuromedin U-8, neuromedin U-23 and/or neuromedin U-25, showing at least an affinity of about  $\log EC_{50} = -9$ .



**Fig.1**





**Fig.2**






Fig. 3a




Fig. 3b

JC13 Rev 1





Fig. 3c




**Fig. 4**



**Fig. 5**

1. A1

A12





2. H1

H12

Human multiple tissue expression array using a human IGS4 probe.

10138.

10138.



9500  
bp  
7500  
bp  
2400 bp  
1350 bp  
240 bp

**Fig. 6**








Fig. 7  
hu-lGS4 expression analysis (MTE blot)



## IGS4 QPCR




Fig. 8

JC13 Rec'd PCT/PTC 22 MAR 2002

REPLACED BY  
ART 34 AMDT

Claims

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
  - a) a nucleotide sequence encoding the IGS4 polypeptide according to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8.
  - b) a nucleotide sequence encoding the polypeptide encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands, in particular a nucleotide sequence corresponding to the SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7.
  - c) a nucleotide sequence having at least 80 % (preferably at least 90%) sequence identity over its entire length to the nucleotide sequence of (a) or (b);
  - d) a nucleotide sequence which is complimentary to the nucleotide sequence of (a) or (b) or (c).
2. The polynucleotide of claim 1 wherein said polynucleotide comprises the nucleotide sequence contained in SEQ ID NO: 1 encoding the IGS4 polypeptide of SEQ ID NO: 2 or the nucleotide sequence contained in SEQ ID NO: 3 encoding the IGS4 polypeptide of SEQ ID NO: 4 or the nucleotide sequence contained in SEQ ID NO: 5 encoding the IGS4 polypeptide of SEQ ID NO: 6 or the nucleotide sequence contained in SEQ ID NO: 7 encoding the IGS4 polypeptide of SEQ ID NO: 8.
3. The polynucleotide of claim 1 wherein said polynucleotide comprises a nucleotide sequence that is at least 80% identical to that of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 or to the sequence of the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands over its entire length.
4. The polynucleotide of claim 3 which is the polynucleotide of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7 or the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands.
5. The polynucleotide of claim 1-4 which is DNA or RNA.



6. An isolated nucleotide sequence encoding an IGS4 neuromedin receptor protein, preferably a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25.
- 5
7. An isolated nucleotide sequence of claim 6 encoding an IGS4 neuromedin receptor protein, said protein exhibiting expression in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea.
- 10
8. An isolated nucleotide sequence encoding an IGS4 neuromedin receptor protein, preferably a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, said protein exhibiting expression in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea, and said nucleotide sequence being selected
- 15
- 20
- from the group of nucleotide sequences as defined in the claims 1 to 5.
9. A DNA or RNA molecule comprising an expression system, wherein said expression system is capable of producing an IGS4 polypeptide comprising an amino acid sequence, which has at least 80% identity with the polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8 or with the polypeptide encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands, when said expression system is present in a compatible host cell.
- 25
- 30 10. An isolated DNA or RNA molecule comprising an expression system, wherein said expression system is capable of producing an IGS4 polypeptide comprising an amino acid sequence which is a neuromedin receptor protein, preferably a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, and exhibiting expression in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus
- 35



accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea.

11. A host cell comprising the expression system of claim 9 or 10.  
5
12. A host cell according to claim 11 which is a yeast cell.
13. A host cell according to claim 11 which is an animal cell.
- 10 14. IGS4 receptor membrane preparation derived from a cell according to claim 11-13.
15. A process for producing an IGS4 polypeptide comprising culturing a host of claim 11-13 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.  
15
16. A process for producing a cell which produces an IGS4 polypeptide comprising transforming or transfecting a host cell with the expression system of claim 9 or 10 such that the host cell, under appropriate culture conditions, produces an IGS4 polypeptide.
- 20 17. An IGS4 polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO: 2, SEQ NO: 4, SEQ NO: 6 or SEQ NO: 8 or to the polypeptide encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands over its entire length.  
25
18. The polypeptide of claim 17 which comprises the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands.  
30
19. An isolated IGS4 polypeptide comprising an amino acid sequence of a neuromedin receptor protein, preferably of a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25.  
35
20. An isolated IGS4 polypeptide of claim 19 comprising an amino acid sequence of a neuromedin receptor protein, said protein exhibiting expression in brain, skeletal muscle,



cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea.

- 5 21. An isolated IGS4 polypeptide comprising an amino acid sequence of a neuromedin receptor protein, preferably a mammalian neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, said protein exhibiting expression in brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, 10 medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate and/or in trachea, and said amino acid sequence being selected from the group of amino acid sequence as defined in the claims 17-18.
- 15 22. An antibody immunospecific for the IGS4 polypeptide of claim 17-21.
23. A method for the treatment of a subject in need of enhanced activity or expression of IGS4 polypeptide of claim 17-21 comprising:  
20 (a) administering to the subject a therapeutically effective amount of an agonist to said receptor; and/or  
(b) providing to the subject an isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the IGS4 polypeptide of SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the polypeptide encoded by the DNA insert contained in the deposit no. CBS102221 or the 25 deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands over its entire length; or a nucleotide sequence complementary to one of said nucleotide sequences in a form so as to effect production of said receptor activity in vivo.  
30 (c) providing to the subject an isolated polynucleotide comprising a nucleotide sequence that encodes an IGS4 neuromedin receptor protein, preferably a mammalian IGS4 neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25.
- 35 24. A method for the treatment of a subject having need to inhibit activity or expression of IGS4 polypeptide of claim 17-21 comprising:



- (a) administering to the subject a therapeutically effective amount of an antagonist to said receptor; and/or
  - (b) administering to the subject a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said receptor; and/or
- 5                   (c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said receptor for its ligand.
25. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of the IGS4 polypeptide of claim 17-21 in a subject comprising:
- 10                  (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said IGS4 polypeptide in the genome of said subject; and/or
- (b) analyzing for the presence or amount of the IGS4 polypeptide expression in a sample derived from said subject.
- 15           26. A method for identifying agonists to the IGS4 polypeptide of claim 17-21 comprising:  
                  (a) contacting a cell which produces a IGS4 polypeptide with a test compound; and  
                  (b) determining whether the test compound effects a signal generated by activation of the IGS4 polypeptide.
- 20           27. An agonist identified by the method of claim 26.
28. A method for identifying agonists to the IGS4 neuromedin receptor protein, preferably to the mammalian IGS4 neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, comprising:
- 25                  (a) contacting a cell which produces a IGS4 neuromedin receptor protein with a test compound; and  
                     (b) determining whether the test compound effects a signal generated by activation of the IGS4 neuromedin receptor protein.
- 30           29. A method for identifying agonists to the IGS4 neuromedin receptor protein according to claim 28, wherein said agonists are effective with regard to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system.
- 35



30. An agonist identified by the method of claim 28 or 29, preferably an agonist being effective with regard to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system.
- 5
31. A method for identifying antagonists to the IGS4 polypeptide of claim 17-21 comprising:  
(a) contacting a cell which produces a IGS4 polypeptide with an agonist; and  
10 (b) determining whether the signal generated by said agonist is diminished in the presence of a candidate compound.
32. An antagonist identified by the method of claim 31.
- 15 33. A method for identifying antagonists to the IGS4 neuromedin receptor protein, preferably to the mammalian IGS4 neuromedin receptor protein, said protein exhibiting high affinity binding for neuromedin U, preferably for neuromedin U-8, for neuromedin U-23 and/or for neuromedin U-25, comprising:  
(a) contacting a cell which produces a IGS4 neuromedin receptor protein with an  
20 agonist; and  
(b) determining whether the signal generated by said agonist is diminished in the presence of a candidate compound.
34. A method for identifying antagonists to the IGS4 neuromedin receptor protein according  
25 to claim 33, wherein said antagonists are effective with regard to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system.
- 30
35. An antagonist identified by the method of claim 33 or 34, preferably an antagonist being effective with regard to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and  
35 disorders of the genitourinary system.



36. A recombinant host cell produced by a method of claim 16 or a membrane thereof expressing an IGS4 polypeptide.

37. A method of creating a genetically modified non-human animal comprising the steps of:

5 (a) ligating the coding portion of a nucleic acid molecule, consisting essentially of a nucleic acid sequence encoding a protein having the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands or a  
10 biologically active portion of one of said sequences, to a regulatory sequence which is capable of driving high level gene expression or expression in a cell type in which the gene is not normally expressed in said animal; or

15 (b) isolation and engineering the coding portion of a nucleic acid molecule, consisting essentially of a nucleic acid sequence encoding a protein having the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands or a biologically active portion of one of said sequences, and reintroducing said sequence in the genome of said animal in such a way that the endogenous gene  
20 alleles, encoding a protein having the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 4, SEQ NO: 6 or SEQ NO: 8 or the amino acid sequence encoded by the DNA insert contained in the deposit no. CBS102221 or the deposit no. CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands or a biologically active portion of one of said sequences, are fully or partially inactivated.

25

38. A method of determining whether a substance is a potential ligand of IGS4 receptor comprising:

30 (a) contacting cells expressing the receptor of one of the claims 17-21 or one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8, or contacting a receptor membrane preparation comprising one of said receptors of one of the claims 17-21 or one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8 with labeled neuromedin U in the presence and in the absence of the substance; and

(b) measuring the binding of neuromedin U to IGS4.



39. A polypeptide according to any of the claims 17-21, further being characterized in that said polypeptide binds neuromedin U, preferably neuromedin U-8, neuromedin U-23 and/or neuromedin U-25, showing at least an affinity of about  $\log EC_{50} = -6$ .
- 5 40. A polypeptide according to any of the claims 17-21, further being characterized in that said polypeptide binds neuromedin U, preferably neuromedin U-8, neuromedin U-23 and/or neuromedin U-25, showing at least an affinity of about  $\log EC_{50} = -9$ .

